

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE**

In re:

MOLECULAR TEMPLATES, INC., *et al.*,¹

Debtors.

Chapter 11

Case No. 25-10739 (BLS)

(Jointly Administered)

**SCHEDULE OF ASSETS AND LIABILITIES
FOR MOLECULAR TEMPLATES OPCO, INC.**

¹ The Debtors in these chapter 11 cases, along with the Debtors' federal tax identification numbers, are: Molecular Templates, Inc. (9596) and Molecular Templates OpCo, Inc. (6035). The Debtors' mailing address is: 124 Washington Street, Ste. 101 Foxboro, MA 02035. All Court filings can be accessed at: <https://www.veritaglobal.net/MolecularTemplates>.



2510739250523000000000006

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE**

In re

MOLECULAR TEMPLATES, INC., *et al.*,

Debtors.¹

Chapter 11

Case No. 25-10739 (BLS)

(Jointly Administered)

**GLOBAL NOTES AND STATEMENT OF LIMITATIONS, METHODOLOGY AND
DISCLAIMER REGARDING THE DEBTORS' SCHEDULES OF ASSETS AND
LIABILITIES AND STATEMENTS OF FINANCIAL AFFAIRS**

The Schedules of Assets and Liabilities (the “Schedules”) and the Statements of Financial Affairs (the “Statements,” and collectively with the Schedules, the “Schedules and Statements”) filed by the above-captioned debtors and debtors in possession (the “Debtors”), in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”), have been prepared by the Debtors’ management in accordance with section 521 of title 11 of the United States Code, 11 U.S.C. §§ 101 *et seq.* (as amended, the “Bankruptcy Code”) and Federal Rule of Bankruptcy Procedure 1007, and are unaudited.

These Global Notes and Statements of Limitations, Methodology and Disclaimer Regarding the Debtors’ Schedules of Assets and Liabilities and Statements of Financial Affairs (the “Global Notes”) pertain to, are incorporated by reference in, and comprise an integral part of all the Schedules and Statements. The Global Notes should be referred to, considered and reviewed in connection with any review of the Schedules and Statements.²

The Schedules and Statements do not purport to represent financial Statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”), nor are they intended to be fully reconciled with the financial Statements of the Debtors. Additionally, the Schedules and Statements contain unaudited information that is subject to further review and potential adjustment.

In preparing the Schedules and Statements, the Debtors relied upon information derived from its books and records that was available at the time of such preparation. Although the Debtors has made reasonable efforts to ensure the accuracy and completeness of such financial information, inadvertent errors or omissions, as well as the discovery of conflicting, revised or subsequent information, may cause material changes to the Schedules and Statements.

¹ The Debtors in these chapter 11 cases, along with the Debtors’ federal tax identification numbers, are: Molecular Templates, Inc. (9596) and Molecular Templates OpCo, Inc. (6035). The Debtors’ mailing address is: 124 Washington Street, Ste. 101 Foxboro, MA 02035. All Court filings can be accessed at: <https://www.veritaglobal.net/MolecularTemplates>.

² These Global Notes are in addition to any specific notes contained in the Debtors’ Schedules and Statements.

The Debtors' management prepared the Schedules and Statements with the assistance of its restructuring advisor, Rock Creek Advisors, and other professionals. Craig Jalbert has signed the Schedules and Statements. Mr. Jalbert is the Chief Executive Officer of, and an authorized signatory for, the Debtors. Mr. Jalbert has not (and could not have) personally verified the accuracy of each Statements and representation contained in the Schedules and Statements, including Statements and representations concerning amounts owed to creditors, classification of such amounts and creditor addresses.

The Schedules, Statements and Global Notes should not be relied upon by any person for information relating to current or future financial conditions, events or performance of the Debtors. Due to numerous unliquidated, contingent and/or disputed claims, summary statistics in the Schedules, Statements and Global Notes are likely not an accurate representation of the Debtors' liabilities on a GAAP basis.

The Debtors and its employees, agents, attorneys, and other professionals shall not be liable for any loss or injury arising out of or caused in whole or in part by the acts, errors or omissions, whether negligent or otherwise, in procuring, compiling, collecting, interpreting, reporting, communicating, or delivering the information contained herein. While every effort has been made to provide accurate and complete information herein, inadvertent errors or omissions may exist. In no event shall the Debtors or its employees, agents, attorneys, or other professionals be liable to any third party for any direct, indirect, incidental, consequential, or special damages (including, but not limited to, damages arising from the disallowance of a potential claim against the Debtors or damages to business reputation, lost business or lost profits), whether foreseeable or not and however caused, even if the Debtors or its employees, agents, attorneys, and other professionals are advised of the possibility of such damages.

Global Notes and Overview of Methodology

1. **Reservation of Rights.** The Debtors reserve and preserve all rights to amend, supplement or otherwise modify the Schedules and Statements from time to time, in all respects, as may be necessary or appropriate, including, without limitation, the right to amend the Schedules and Statements with respect to a claim (including, but not limited to: amending the description or designation of any claim; disputing or otherwise asserting offsets or defenses to any claim reflected in the Schedules and Statements as to amount, liability, priority, status or classification; subsequently designating any claim as "disputed," "contingent" or "unliquidated;" or objecting to the extent, validity, enforceability, priority or avoidability of any claim). Any failure to designate a claim in the Schedules and Statements as "disputed," "contingent" or "unliquidated" does not constitute an admission by the Debtors that such claim or amount is not "disputed," "contingent" or "unliquidated." Listing a claim does not constitute an admission of liability by the Debtors.

Further, nothing contained in the Schedules and Statements shall constitute a waiver of rights with respect to these chapter 11 cases, including, without limitation, with respect to matters involving objections to claims, equitable subordination, defense, characterization or re-characterization of contracts, assumption or rejection of contracts under the provisions of chapter

3 of the Bankruptcy Code and/or causes of action arising under the provisions of chapter 5 of the Bankruptcy Code or any other relevant laws to recover assets or avoid transfers. Any specific reservation and preservation of rights contained elsewhere in the Global Notes does not limit in any respect the general reservation and preservation of rights contained in this or the preceding paragraph.

2. Description of the Case and “as of” Information Date. On April 20, 2025 (the “Petition Date”), the Debtors filed voluntary petitions with the Bankruptcy Court under chapter 11 of the Bankruptcy Code. The Debtors continue to manage their assets as Debtors in possession pursuant to sections 1107(a) and 1108 of the Bankruptcy Code. Unless otherwise stated, asset and liability information is as of the Petition Date. As more fully described below, the Debtors were required to make certain estimates and assumptions that affect the reported amounts within the Schedules and Statements.

Additionally, the Debtors have made every effort to allocate liabilities between the prepetition and postpetition periods based on information available and research conducted in connection with the preparation of the Schedules and Statements. As additional information becomes available to, and further research is conducted by, the Debtors, the Debtors’ allocation of liabilities between prepetition and postpetition periods may change.

3. Basis of Presentation. For financial reporting purposes, the Debtors historically prepared consolidated financial Statements. The Schedules and Statements reflect the assets and liabilities of the Debtors on the basis of the Debtors’ unaudited records. Furthermore, the Schedules and Statements do not purport to represent financial Statements prepared in accordance with GAAP, nor are they intended to reconcile to the financial Statements previously distributed to certain third parties. Accordingly, the totals listed in the Schedules and Statements differ, at times materially, from the consolidated financial reports prepared by the Debtors for financial reporting purposes or otherwise.

To the extent that the Debtors shows more assets than liabilities, this is not an admission that the Debtors were solvent at the Petition Date or at any time prior to the Petition Date.

4. Recharacterization. Notwithstanding the Debtors’ reasonable efforts to properly characterize, classify, categorize and designate certain claims, assets, contracts, leases and other items reported in the Schedules and Statements, the Debtors may nevertheless seek to recharacterize, reclassify, recategorize, redesignate, add or delete items. Accordingly, the Debtors reserve and preserve all of their rights to recharacterize, reclassify, recategorize, redesignate, add or delete items reported in the Schedules and Statements at a later time as is necessary or appropriate as additional information becomes available, including, without limitation, whether contracts or leases listed in the Schedules and Statements were deemed executory or unexpired as of the Petition Date and remain executory or unexpired postpetition.

5. Excluded Assets and Liabilities. In addition, certain immaterial assets and liabilities may have been excluded. The liabilities listed on the Schedules and Statements do not reflect a complete analysis of claims under section 503(b)(9) of the Bankruptcy Code.

Accordingly, the Debtors reserve and preserve their rights to dispute or challenge the validity of all claims asserted under section 503(b)(9) of the Bankruptcy Code.

6. Insiders. For purposes of the Schedules and Statements, the Debtors define “insiders” pursuant to section 101(31) of the Bankruptcy Code as: (a) directors; (b) officers; (c) persons in control of the Debtors; (d) relatives of directors, officers, or persons in control of the Debtors; and (e) affiliates. Persons listed as “insiders” have been included for informational purposes only, and including them in the Schedules and Statements shall not constitute an admission that those persons are insiders for purposes of section 101(31) of the Bankruptcy Code.

The Debtors do not take any position with respect to: (a) such person’s influence over the control of the Debtors; (b) the management responsibilities or functions of such individual; (c) the decision-making or corporate authority of such individual; or (d) whether such individual could successfully argue that he or she is not an “insider” under applicable law, including the federal securities laws and section 101(31) of the Bankruptcy Code, or with respect to any theories of liability or for any other purpose. As such, the Debtors reserve and preserve all rights with respect to the foregoing issues.

7. Executory Contracts and Unexpired Leases. Nothing contained in or omitted from the Schedules and Statements is or shall be construed as an admission as to the determination of the legal status of any contract or lease, including whether any lease is a true lease or a financing arrangement, whether such contract or lease is an executory contract or unexpired lease, or whether such contract or lease is binding, valid and enforceable. The Debtors reserve and preserve all rights with respect to all such issues.

While every effort has been made to ensure the completeness and accuracy of the listing of executory contracts and unexpired leases, inadvertent errors or omissions may have occurred. The contracts, agreements and leases listed on Schedule G may have expired or may have been modified, amended, or supplemented from time to time by various amendments, restatements, waivers, estoppel certificates, letters and other documents, instruments and agreements which may not be listed therein. Such rights, powers, duties and obligations are not set forth on Schedule G. Certain of the executory contracts or unexpired leases may not have been memorialized and could be subject to dispute. Similarly, the absence of a contract or lease from Schedule G does not constitute an admission that such contract or lease is not executory. Certain of the leases and executory contracts listed on Schedule G were rejected pursuant to the *First Omnibus Order (I) Authorizing the Debtors to (A) Reject Certain Unexpired Leases Nunc Pro Tunc to the Petition Date, and (B) Abandon Any Personal Property that Remains at Leased Premises, and (II) Granting Related Relief* (D.I. 68).

In addition, the Debtors reserve and preserve all rights, claims and causes of action with respect to the contracts and leases listed in the Schedules and Statements, including the rights to dispute or challenge the characterization or the structure of any transaction, document or instrument.

8. Classifications. Listing a claim on (i) Schedule E/F, Part 1 as “priority,” (ii) Schedules E/F, Part 1 or 2 as “unsecured,” or (iii) Schedule G as “executory” or “unexpired,” is

not a waiver of the Debtors' rights to recharacterize or reclassify such claims, contracts, leases or, amend such schedules.

9. Causes of Action. Despite its reasonable efforts to identify all known assets, the Debtors may not have identified and/or listed as assets in the Schedules and Statements all of its causes of action or potential causes of action against third parties (and in particular has not identified or listed causes of action arising under the provisions of chapter 5 of the Bankruptcy Code and any other relevant nonbankruptcy laws to recover assets or avoid transfers). The Debtors reserve and preserve its rights with respect to any claim, cause of action (including avoidance actions), controversy, right of setoff, recoupment, cross-claim, or counterclaim; and any demand, right, action, lien, indemnity, guaranty, suit, obligation, liability, damage, judgment, account, defense, power, privilege, license or franchise, in each case of any kind or character whatsoever, known or unknown, fixed or contingent, mature or unmatured, liquidated or unliquidated, disputed or undisputed, secured or unsecured, direct or derivative, whether arising before, on, or after the Petition Date, in contract or in tort, in law or in equity, or otherwise (collectively, "Causes of Action"), and neither these Global Notes nor the Schedules and Statements shall be deemed a waiver of any claims or Causes of Action or in any way prejudice or impair the assertion of such Causes of Action.

10. Summary of Significant Reporting Policies. The following conventions were adopted by the Debtors in the preparation of the Schedules and Statements:

(a) Book Value. Unless otherwise noted, each asset and liability of the Debtors is shown on the basis of the net book value of the asset or liability in accordance with the Debtors' accounting and/or tax books and records as of the Petition Date, and is not based upon any estimate of its current market values.

(b) Cash. Any cash balances in the Debtors' bank accounts set forth in Schedule A/B are based on the book balance as of the beginning of business on the Petition Date.

(c) Property and Equipment: Owned. Fixed assets are recorded at cost. Depreciation is computed on a straight line method over the estimated useful life of the asset.

(d) Liens and Encumbrances on Assets. In the ordinary course of the Debtors' business, tax liens and other encumbrances (*e.g.*, judgment liens) are occasionally filed against assets owned by the Debtors. The Debtors have made a reasonable, good faith effort to include all liens on Schedule D, but may have inadvertently failed to include an existing lien because of, among other things, the possibility that a lien may have been imposed after the Uniform Commercial Code searches were performed or a vendor may not have filed the requisite perfection documentation.

(e) Undetermined Amounts. The description of any amounts as "unknown," "TBD" or "undetermined" is not intended to reflect upon the materiality of such amount.

11. Setoffs. The Debtors incurred certain offsets and other similar rights during the ordinary course of its business. Offsets in the ordinary course can result from various items, including, without limitation, pricing discrepancies, returns, refunds, warranties, debit memos, credits, and other disputes between the Debtors and its suppliers. These offsets and other similar rights are consistent with the ordinary course of business in the Debtors' industry and are not tracked separately. Therefore, although such offsets and other similar rights may have been accounted for when certain amounts were included in the Schedules and Statements, offsets are not independently accounted for, and as such, are or may be excluded from the Debtors' Schedules and Statements.

12. Estimates and Assumptions. To prepare and file the Schedules and Statements in accordance with the deadlines established in the chapter 11 case, the Debtors was required to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and reported revenue and expenses. The Debtors reserves and preserves all rights to amend the reported amounts of assets, liabilities, revenue and expenses to reflect changes in those estimates and assumptions.

13. Confidential or Sensitive Information. There may be instances where certain information in the Schedules and Statements was not included or redacted due to the nature of an agreement between the Debtors and a third party, concerns about the confidential or commercially sensitive nature of certain information, concerns for the privacy of an individual, or due to privacy-related laws and/or regulatory regimes.

14. Currency. Unless otherwise indicated, all amounts are reflected in U.S. dollars.

15. Totals. All totals that are included in the Schedules and Statements represent totals of all the known amounts included in the Schedules and Statements. To the extent there are unknown or undetermined amounts, the actual total may be different than the listed total. As previously stated, the description of an amount as "unknown" or "undetermined" is not intended to reflect upon the materiality of such amount.

Specific Schedule Disclosures

1. Schedule A/B - Assets – Real and Personal Property:

- a. **Part 1 – Cash and cash equivalents.** The Debtors' Cash Management System is comprised of four (4) bank accounts. The Debtors' primary postpetition cash management bank is with Silicon Valley Bank. Further details with respect to the Cash Management System are provided in the Cash Management Motion [D.I. 5]. The cash amount listed is as of the Petition Date and reflects the bank balance, not the net book value.
- b. **Part 2 – Deposits and Prepayments.** Part 2 identifies previous payments made on behalf of the Debtors for services or prepayments of services or other

obligations.

- c. **Part 7 – Office furniture, fixtures, and equipment; and collectibles.** Actual realizable values may vary significantly relative to net book values as of the Petition Date. Additionally, in an effort to reduce the volume of the disclosures that would be otherwise applicable, the Debtors is disclosing its fixed assets at the category level.
- d. **Part 8 – Machinery, equipment, and vehicles.** Machinery and Equipment leased by the Debtors is listed on both Schedule A/B and on Schedule G. Actual realizable values of the assets identified may vary significantly relative to net book values as of the Petition Date.
- e. **Part 9 – Real Property.** Property leased by the Debtors is listed on both Part 9 of Schedule A/B and on Schedule G. Furthermore, the property value is scheduled in accordance with the Debtors’ books and records, which may not comport with the legal owner of record. Actual realizable values of the assets identified may vary significantly relative to recorded values as of the Petition Date, which reflect net book value. The Debtors reserve all rights to recharacterize its interests in real property at a later date.
- f. **Part 10 – Intangibles and intellectual property.** Part 10 identifies the various trademarks, patents, and website domains owned and maintained by the Debtors. The Schedules may not list the value of such intangible assets as no recent appraisals have been performed. Various software licenses the Debtors used for their operation, which are easily obtainable and hold minimal value, are not included.
- g. **Part 11 – All other assets.** Potential preference actions and/or fraudulent transfer actions were not listed because the Debtors has not completed an analysis of such potential claims. The Debtors’ failure to list any cause of action, claim, or right of any nature is not an admission that such cause of action, claim, or right does not exist and should not be construed as a waiver of such cause of action, claim, or right.

2. **Schedule D – Creditors Who Have Claims Secured by Property:**

- a. The claims listed on Schedule D arose and were incurred on various dates. To the best of the Debtors’ knowledge, all claims listed on Schedule D arose, or were incurred, before the Petition Date.
- b. Except as otherwise agreed or stated pursuant to a stipulation, agreed order, or general order entered by the Court that is or becomes final, the Debtors and/or their estates reserve the right to dispute and challenge the validity, perfection, or immunity from avoidance of any lien purported to be granted or perfected in any specific asset to a creditor listed on Schedule D of any Debtors and, subject to the

foregoing limitations, note as follows: (i) although the Debtors may have scheduled claims of various creditors as secured claims for informational purposes, no current valuation of the Debtors' assets in which such creditors may have a lien has been undertaken, and (ii) the descriptions provided on Schedule D and herein are intended to be a summary. Reference to the applicable loan agreements and related documents is necessary for a complete description of the collateral and the nature, extent, and priority of any liens. Detailed descriptions of the Debtors' prepetition debt structure, guarantees, and descriptions of collateral relating to each obligation, if any, contained on Schedule D are contained in the *Declaration of Craig Jalbert in Support of Debtors' Chapter 11 Petitions and First Day Motions* [Docket No. 15] (the "First Day Declaration").

- c. Schedule D does not include beneficiaries of letters of credit. Although the claims of such parties may be secured by a letter of credit, the Debtors' obligations under the letters of credit run to the issuers thereof, and not to the beneficiaries thereof.
- d. The Debtors have not listed on Schedule D any parties whose claims may be secured through rights of setoff, deposits, or advance payments posted by, or on behalf of, the Debtors, or judgment or statutory lien rights. The Debtors have not investigated which of the claims may include such rights, and their population is currently unknown.

3. Schedule E/F – Creditors Who Have Unsecured Claims:

- a. **Part 1 – List all creditors with priority unsecured claims.** The Debtors' analysis of any potential priority claims is ongoing.

The liabilities listed on the Schedules do not reflect any analysis of claims under section 503(b)(9) of the Bankruptcy Code. Accordingly, the Debtors reserve their rights to dispute or challenge the validity of any asserted claims under section 503(b)(9) of the Bankruptcy Code or the characterization of the structure of any such transaction or any document or instrument related to any creditor's claim.

- b. **Part 2 – Creditors with Nonpriority Unsecured Claims.** Schedule E/F Part 2 reflects the prepetition amounts owing to counterparties to executory contracts and unexpired leases. Such prepetition amounts, however, may be paid in connection with the assumption, or assumption and assignment, of executory contracts or unexpired leases. Additionally, Schedule E/F Part 2 does not include potential rejection damage claims, if any, of the counterparties to executory contracts and unexpired leases that have been or may be rejected postpetition.

4. Schedule G – Executory Contracts and Unexpired Leases.

- a. Although commercially reasonable efforts have been made to ensure the accuracy of Schedule G regarding executory contracts and unexpired leases (collectively, the "Agreements") as of the filing of the Statements and Schedules, the Debtors' collection and review process of the Agreements is ongoing, and inadvertent errors,

omissions, or over- or under-inclusion may have occurred. The Debtors may have entered into various other types of Agreements in the ordinary course of their business, such as indemnity agreements, supplemental agreements, amendments/letter agreements, master service agreements, and confidentiality agreements, that may not be set forth in Schedule G. The Debtors have not included on Schedule G the engagement letters with any of the Debtors' professionals that have been retained pursuant to an order of the Court in these Chapter 11 Cases, which agreements have been publicly filed with the Court. Omission of a contract or agreement from Schedule G does not constitute an admission that such omitted contract or agreement is not an executory contract or unexpired lease. Schedule G may be amended at any time to add any omitted Agreements. Likewise, the listing of an Agreement on Schedule G does not constitute an admission that such Agreement is an executory contract or unexpired lease, that such Agreement was in effect on the Petition Date, or that such Agreement is valid or enforceable. The Agreements listed on Schedule G may have expired or may have been modified, amended, or supplemented from time to time by various amendments, restatements, waivers, estoppel certificates, letters and other documents, instruments, and agreements which may not be listed on Schedule G.

Specific Notes with Respect to the Debtors' Statements of Financial Affairs

1. **Part 1: Income. Questions 1.** The Debtors receive a certain amount of cash up-front from specific contracts that is recorded as deferred revenue and recognized into revenue over time as certain milestones are completed.
2. **Part 2: Income. Questions 3 and 4.** In the ordinary course of their business, the Debtors maintain a cash management system in which the Debtors disburse funds from their operating account that are used to satisfy their ordinary course operating expenses and financial obligations as further explained in the Cash Management Motion. Consequently, most, if not all, payments to creditors and insiders listed in response to Questions 3 and 4 of the Debtors' Statements reflect payments made pursuant to the Debtors' cash management system described in the Cash Management Motion.
3. **Part 3: Legal Action or Assignments. Question 7.** Information provided on Statement 7 includes only those legal disputes and administrative proceedings that are formally recognized by an administrative, judicial, or other adjudicative forum. The Debtors used commercially reasonable efforts to identify all pending litigation and assign appropriate descriptions thereto using information available to the Debtors. In the event that the Debtors discover additional information pertaining to the legal action identified in response to Statement 7, the Debtors will use reasonable efforts to supplement the Statements in light thereof.
4. **Part 6: Certain Payments or Transfers. Question 11.** All payments for services of any entities that provided consultation concerning debt counseling or restructuring services, relief under the Bankruptcy Code, or preparation of a petition in bankruptcy within one (1) year immediately preceding the Petition Date are listed on the applicable Debtors' response

to Statements 11.

5. **Part 13: Details About the Debtors' Business or Connections to Any Business. Question 26(d).** Molecular Templates, Inc. is a registrant with the Securities Exchange Commission and files periodic consolidated financial reports that include financial Statements that are available to the public. The Debtors have also provided financial Statements in the ordinary course of business to numerous financial institutions, creditors, and other parties within two years immediately before the Petition Date. Considering the number of such recipients and the possibility that such information may have been shared with parties without the Debtors' knowledge or consent, the Debtors have not disclosed any parties that may have received such financial Statements for the purposes of Statements 26(d).
6. **Part 13: Details About the Debtors' Business or Connections to Any Business. Question 30.** For information related to payments and transfers to insiders, please refer to SOFA question number four.

Fill in this information to identify the case:Debtor name **Molecular Templates Opco, Inc.**United States Bankruptcy Court for the: **DISTRICT OF DELAWARE**Case number (if known) **25-10740**☐ Check if this is an amended filing**Official Form 206Sum
Summary of Assets and Liabilities for Non-Individuals**

12/15

Part 1: Summary of Assets**1. Schedule A/B: Assets-Real and Personal Property** (Official Form 206A/B)

1a. Real property: Copy line 88 from <i>Schedule A/B</i>	\$ 0.00
1b. Total personal property: Copy line 91A from <i>Schedule A/B</i>	\$ 306,542.28
1c. Total of all property: Copy line 92 from <i>Schedule A/B</i>	\$ 306,542.28

Part 2: Summary of Liabilities

2. Schedule D: Creditors Who Have Claims Secured by Property (Official Form 206D) Copy the total dollar amount listed in Column A, <i>Amount of claim</i> , from line 3 of <i>Schedule D</i>	\$ 25,666,747.07
3. Schedule E/F: Creditors Who Have Unsecured Claims (Official Form 206E/F)	
3a. Total claim amounts of priority unsecured claims: Copy the total claims from Part 1 from line 5a of <i>Schedule E/F</i>	\$ 0.00
3b. Total amount of claims of nonpriority amount of unsecured claims: Copy the total of the amount of claims from Part 2 from line 5b of <i>Schedule E/F</i>	+\$ 3,760,798.45
4. Total liabilities Lines 2 + 3a + 3b	\$ 29,427,545.52

Fill in this information to identify the case:Debtor name **Molecular Templates Opco, Inc.**United States Bankruptcy Court for the: **DISTRICT OF DELAWARE**Case number (if known) **25-10740**☐ Check if this is an amended filing**Official Form 206A/B****Schedule A/B: Assets - Real and Personal Property**

12/15

Disclose all property, real and personal, which the debtor owns or in which the debtor has any other legal, equitable, or future interest. Include all property in which the debtor holds rights and powers exercisable for the debtor's own benefit. Also include assets and properties which have no book value, such as fully depreciated assets or assets that were not capitalized. In Schedule A/B, list any executory contracts or unexpired leases. Also list them on *Schedule G: Executory Contracts and Unexpired Leases* (Official Form 206G).

Be as complete and accurate as possible. If more space is needed, attach a separate sheet to this form. At the top of any pages added, write the debtor's name and case number (if known). Also identify the form and line number to which the additional information applies. If an additional sheet is attached, include the amounts from the attachment in the total for the pertinent part.

For Part 1 through Part 11, list each asset under the appropriate category or attach separate supporting schedules, such as a fixed asset schedule or depreciation schedule, that gives the details for each asset in a particular category. List each asset only once. In valuing the debtor's interest, do not deduct the value of secured claims. See the instructions to understand the terms used in this form.

Part 1: Cash and cash equivalents**1. Does the debtor have any cash or cash equivalents?**

- ☐ No. Go to Part 2.
☒ Yes Fill in the information below.

All cash or cash equivalents owned or controlled by the debtor**Current value of debtor's interest****3. Checking, savings, money market, or financial brokerage accounts (Identify all)**

Name of institution (bank or brokerage firm)

Type of account

Last 4 digits of account number

	Name of institution (bank or brokerage firm)	Type of account	Last 4 digits of account number	Current value of debtor's interest
3.1.	Silicon Valley Bank (SVB)	Checking	0682	\$2,387.09
3.2.	Silicon Valley Bank (SVB)	MMA	1589	\$0.00
3.3.	Silicon Valley Bank (SVB)	MMA	4375	\$0.00
3.4.	Silicon Valley Bank (SVB)	MMA	6034	\$0.00
3.5.	Silicon Valley Bank (SVB)	MMA	3119	\$0.00
3.6.	U.S. Bank	Investment	7490	\$151.53

Debtor **Molecular Templates Opco, Inc.**
NameCase number (If known) **25-10740**

3.7. U.S. Bank	Investment	5075	\$375.28
-----------------------	-------------------	-------------	-----------------

4. **Other cash equivalents** (Identify all)5. **Total of Part 1.**

Add lines 2 through 4 (including amounts on any additional sheets). Copy the total to line 80.

\$2,913.90

Part 2: Deposits and Prepayments

6. Does the debtor have any deposits or prepayments?

- ☐ No. Go to Part 3.
- ☒ Yes Fill in the information below.

7. **Deposits, including security deposits and utility deposits**

Description, including name of holder of deposit

8. **Prepayments, including prepayments on executory contracts, leases, insurance, taxes, and rent**

Description, including name of holder of prepayment

8.1. Prepaid Insurance - Chubb & Son (Workers Comp)	\$3,804.22
--	-------------------

8.2. Prepaid Insurance - Chubb & Son (General)	\$22,716.72
---	--------------------

8.3. Prepaid Insurance - Chubb & Son (Umbrella)	\$8,472.97
--	-------------------

8.4. Prepaid Insurance - Chubb & Son (Auto)	\$721.60
--	-----------------

8.5. Prepaid Insurance - Marsh & McLennan (Fiduciary Liability)	\$927.00
--	-----------------

8.6. Prepaid Insurance - Marsh & McLennan (Employment)	\$6,633.75
---	-------------------

8.7. Prepaid Insurance - Marsh & McLennan (Crime)	\$1,721.00
--	-------------------

8.8. Prepaid Insurance - Marsh & McLennan (Cyber)	\$2,733.96
--	-------------------

8.9. Prepaid Insurance - Marsh & McLennan (Excess Umbrella)	\$3,787.50
--	-------------------

8.17	Prepaid Other - Boomi	\$600.00
------	-----------------------	----------

\$288,716.33

10. Does the debtor have any accounts receivable?

- ☐ No. Go to Part 4.
- ☒ Yes Fill in the information below.

11b. Over 90 days old:	<u>14,912.05</u>	-	<u>0.00</u>	=....	<u>\$14,912.05</u>
	face amount		doubtful or uncollectible accounts		

\$14,912.05

Official Form 206A/B Schedule A/B Assets - Real and Personal Property page 3

Debtor Molecular Templates Opco, Inc.
NameCase number (If known) 25-10740**13. Does the debtor own any investments?**

- ☒ No. Go to Part 5.
☐ Yes Fill in the information below.

Part 5: Inventory, excluding agriculture assets**18. Does the debtor own any inventory (excluding agriculture assets)?**

- ☒ No. Go to Part 6.
☐ Yes Fill in the information below.

Part 6: Farming and fishing-related assets (other than titled motor vehicles and land)**27. Does the debtor own or lease any farming and fishing-related assets (other than titled motor vehicles and land)?**

- ☒ No. Go to Part 7.
☐ Yes Fill in the information below.

Part 7: Office furniture, fixtures, and equipment; and collectibles**38. Does the debtor own or lease any office furniture, fixtures, equipment, or collectibles?**

- ☒ No. Go to Part 8.
☐ Yes Fill in the information below.

Part 8: Machinery, equipment, and vehicles**46. Does the debtor own or lease any machinery, equipment, or vehicles?**

- ☒ No. Go to Part 9.
☐ Yes Fill in the information below.

Part 9: Real property**54. Does the debtor own or lease any real property?**

- ☒ No. Go to Part 10.
☐ Yes Fill in the information below.

Part 10: Intangibles and intellectual property**59. Does the debtor have any interests in intangibles or intellectual property?**

- ☐ No. Go to Part 11.
☒ Yes Fill in the information below.

	General description	Net book value of debtor's interest (Where available)	Valuation method used for current value	Current value of debtor's interest
60.	Patents, copyrights, trademarks, and trade secrets See Attachment			
61.	Internet domain names and websites			
62.	Licenses, franchises, and royalties MT-0169 Licensing Agreement - Millennium Pharmaceuticals, Inc. (wholly-owned subsidiary of Takeda Pharmaceutical Company, Limited)	Unknown	Recent cost	Unknown

Debtor Molecular Templates Opco, Inc.
NameCase number (If known) 25-10740MT-6402 Licensing Agreement - Abeome CorporationUnknownRecent costUnknownMT-8421 Licensing Agreement - GenScript Probio USA Inc.UnknownRecent costUnknown63. **Customer lists, mailing lists, or other compilations**64. **Other intangibles, or intellectual property**65. **Goodwill**66. **Total of Part 10.**

Add lines 60 through 65. Copy the total to line 89.

\$0.0067. **Do your lists or records include personally identifiable information of customers** (as defined in 11 U.S.C. §§ 101(41A) and 107?☒ No☐ Yes68. **Is there an amortization or other similar schedule available for any of the property listed in Part 10?**☒ No☐ Yes69. **Has any of the property listed in Part 10 been appraised by a professional within the last year?**☒ No☐ Yes**Part 11: All other assets**70. **Does the debtor own any other assets that have not yet been reported on this form?**

Include all interests in executory contracts and unexpired leases not previously reported on this form.

☐ No. Go to Part 12.☒ Yes Fill in the information below.Current value of
debtor's interest71. **Notes receivable**

Description (include name of obligor)

72. **Tax refunds and unused net operating losses (NOLs)**

Description (for example, federal, state, local)

Net Operating Loss Carryover (NOL)Tax year 2023Unknown73. **Interests in insurance policies or annuities**74. **Causes of action against third parties (whether or not a lawsuit has been filed)**75. **Other contingent and unliquidated claims or causes of action of every nature, including counterclaims of the debtor and rights to set off claims**76. **Trusts, equitable or future interests in property**77. **Other property of any kind not already listed** *Examples:* Season tickets, country club membership

Debtor **Molecular Templates Opco, Inc.**
NameCase number (if known) **25-10740**78. **Total of Part 11.**

Add lines 71 through 77. Copy the total to line 90.

<u>\$0.00</u>

79. **Has any of the property listed in Part 11 been appraised by a professional within the last year?**☒ No☐ Yes

Debtor **Molecular Templates Opco, Inc.**
NameCase number (If known) **25-10740****Part 12: Summary**

In Part 12 copy all of the totals from the earlier parts of the form

Type of property	Current value of personal property	Current value of real property
80. Cash, cash equivalents, and financial assets. <i>Copy line 5, Part 1</i>	\$2,913.90	
81. Deposits and prepayments. <i>Copy line 9, Part 2.</i>	\$288,716.33	
82. Accounts receivable. <i>Copy line 12, Part 3.</i>	\$14,912.05	
83. Investments. <i>Copy line 17, Part 4.</i>	\$0.00	
84. Inventory. <i>Copy line 23, Part 5.</i>	\$0.00	
85. Farming and fishing-related assets. <i>Copy line 33, Part 6.</i>	\$0.00	
86. Office furniture, fixtures, and equipment; and collectibles. <i>Copy line 43, Part 7.</i>	\$0.00	
87. Machinery, equipment, and vehicles. <i>Copy line 51, Part 8.</i>	\$0.00	
88. Real property. <i>Copy line 56, Part 9.....></i>		\$0.00
89. Intangibles and intellectual property. <i>Copy line 66, Part 10.</i>	\$0.00	
90. All other assets. <i>Copy line 78, Part 11.</i>	\$0.00	
91. Total. Add lines 80 through 90 for each column	\$306,542.28	\$0.00
92. Total of all property on Schedule A/B. Add lines 91a+91b=92		\$306,542.28

SCHEDULE AB 60 ATTACHMENT
 Patents, Copyrights, Trademarks, and Trade Secrets

Schedule A/B 60*Patents, copyrights, trademarks, and trade secrets*

Reference No.	Country	Status	Application No.	Filing Date	Patent No.	Issue Date	Patent / Application Title	Description
MTEM-002	AU	Granted	2015209065	26-Jan-2015	2015209065	19-Sep-2019	DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES FOR APPLICATIONS IN MAMMALS	Deimmunized SLT-A with disrupted B- cell epitopes
MTEM-002	AU	Granted	2019204364	26-Jan-2015	2019204364	8-Apr-2021	DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES FOR APPLICATIONS IN MAMMALS	Deimmunized SLT-A with disrupted B- cell epitopes
MTEM-002	AU	Granted	2020294212	26-Jan-2015	2020294212	1-Dec-2022	DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES FOR APPLICATIONS IN MAMMALS	Deimmunized SLT-A with disrupted B- cell epitopes
MTEM-002	AU	Granted	2022256081	10-Oct-2022	2022256081	4-Apr-2024	DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES FOR APPLICATIONS IN MAMMALS	Deimmunized SLT-A with disrupted B- cell epitopes
MTEM-002	CA	Published	2937407	26-Jan-2015			DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES FOR APPLICATIONS IN MAMMALS	Deimmunized SLT-A with disrupted B- cell epitopes
MTEM-002	EP	Granted	15704153.4	26-Jan-2015	3099705	19-Jun-2019	DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES FOR APPLICATIONS IN MAMMALS	Deimmunized SLT-A with disrupted B- cell epitopes
MTEM-002	EP	Published	19173105.8	26-Jan-2015			DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES FOR APPLICATIONS IN MAMMALS	Deimmunized SLT-A with disrupted B- cell epitopes
MTEM-002	IL	Granted	246632	26-Jan-2015	246632	1-Jul-2020	DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES FOR APPLICATIONS IN MAMMALS	Deimmunized SLT-A with disrupted B- cell epitopes
MTEM-002	IL	Granted	273035	26-Jan-2015	273035	2-Mar-2022	DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES FOR APPLICATIONS IN MAMMALS	Deimmunized SLT-A with disrupted B- cell epitopes
MTEM-002	IL	Granted	287490	26-Jan-2015	287490	3-Nov-2022	DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES FOR APPLICATIONS IN MAMMALS	Deimmunized SLT-A with disrupted B- cell epitopes

SCHEDULE AB 60 ATTACHMENT

Patents, Copyrights, Trademarks, and Trade Secrets

Schedule A/B 60*Patents, copyrights, trademarks, and trade secrets*

Reference No.	Country	Status	Application No.	Filing Date	Patent No.	Issue Date	Patent / Application Title	Description
MTEM-002	IL	Granted	294746	26-Jan-2015	294746	4-Mar-2024	DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES FOR APPLICATIONS IN MAMMALS	Deimmunized SLT-A with disrupted B- cell epitopes
MTEM-002	IN	Granted	201617025764	26-Jan-2015	434697	14-Jun-2023	DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES FOR APPLICATIONS IN MAMMALS	Deimmunized SLT-A with disrupted B- cell epitopes
MTEM-002	JP	Granted	2016-546493	26-Jan-2015	6646584	15-Jan-2020	DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES FOR APPLICATIONS IN MAMMALS	Deimmunized SLT-A with disrupted B- cell epitopes
MTEM-002	JP	Granted	2021-12325	21-Jun-2021	7126729	19-Aug-2022	DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES FOR APPLICATIONS IN MAMMALS	Deimmunized SLT-A with disrupted B- cell epitopes
MTEM-002	JP	Granted	2022-127059	9-Aug-2021	7402256	13-Dec-2023	DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES FOR APPLICATIONS IN MAMMALS	Deimmunized SLT-A with disrupted B- cell epitopes
MTEM-002	KR	Granted	10-2022-7001129	12-Jan-2022	10-2500408	13-Feb-2023	DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES FOR APPLICATIONS IN MAMMALS	Deimmunized SLT-A with disrupted B- cell epitopes
MTEM-002	KR	Granted	10-2023-7005041	13-Feb-2023	10-2692200	01-Aug 2024	DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES FOR APPLICATIONS IN MAMMALS	Deimmunized SLT-A with disrupted B- cell epitopes
MTEM-002	MX	Granted	MX/a/2016/009809	26-Jan-2015	394993	24-Aug-2022	DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES FOR APPLICATIONS IN MAMMALS	Deimmunized SLT-A with disrupted B- cell epitopes
MTEM-002	MX	Pending	MX/a/2022/010376	23-Aug-2022			DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES FOR APPLICATIONS IN MAMMALS	Deimmunized SLT-A with disrupted B- cell epitopes
MTEM-002	CH	Granted	15704153.4	26-Jan-2015	3099705	19-Jun-2019	DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES FOR APPLICATIONS IN MAMMALS	Deimmunized SLT-A with disrupted B- cell epitopes

SCHEDULE AB 60 ATTACHMENT
 Patents, Copyrights, Trademarks, and Trade Secrets

Schedule A/B 60

Patents, copyrights, trademarks, and trade secrets

Reference No.	Country	Status	Application No.	Filing Date	Patent No.	Issue Date	Patent / Application Title	Description
MTEM-002	DE	Granted	15704153.4	26-Jan-2015	3099705	19-Jun-2019	DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES FOR APPLICATIONS IN MAMMALS	Deimmunized SLT-A with disrupted B- cell epitopes
MTEM-002	ES	Granted	15704153.4	26-Jan-2015	3099705	19-Jun-2019	DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES FOR APPLICATIONS IN MAMMALS	Deimmunized SLT-A with disrupted B- cell epitopes
MTEM-002	FR	Granted	15704153.4	26-Jan-2015	3099705	19-Jun-2019	DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES FOR APPLICATIONS IN MAMMALS	Deimmunized SLT-A with disrupted B- cell epitopes
MTEM-002	GB	Granted	15704153.4	26-Jan-2015	3099705	19-Jun-2019	DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES FOR APPLICATIONS IN MAMMALS	Deimmunized SLT-A with disrupted B- cell epitopes
MTEM-002	IE	Granted	15704153.4	26-Jan-2015	3099705	19-Jun-2019	DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES FOR APPLICATIONS IN MAMMALS	Deimmunized SLT-A with disrupted B- cell epitopes
MTEM-002	IT	Granted	502019000071471	26-Jan-2015	3099705	19-Jun-2019	DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES FOR APPLICATIONS IN MAMMALS	Deimmunized SLT-A with disrupted B- cell epitopes
MTEM-002	LI	Granted	15704153.4	26-Jan-2015	3099705	19-Jun-2019	DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES FOR APPLICATIONS IN MAMMALS	Deimmunized SLT-A with disrupted B- cell epitopes
MTEM-002	NL	Granted	15704153.4	26-Jan-2015	3099705	19-Jun-2019	DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES FOR APPLICATIONS IN MAMMALS	Deimmunized SLT-A with disrupted B- cell epitopes
MTEM-002	HK	Granted	16114241.0	26-Jan-2015	1226083	7-Feb-2020	DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES FOR APPLICATIONS IN MAMMALS	Deimmunized SLT-A with disrupted B- cell epitopes
MTEM-002	HK	Published	42020005599.4	9-Apr-2020			DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES FOR APPLICATIONS IN MAMMALS	Deimmunized SLT-A with disrupted B- cell epitopes

SCHEDULE AB 60 ATTACHMENT
Patents, Copyrights, Trademarks, and Trade Secrets

Schedule A/B 60

Patents, copyrights, trademarks, and trade secrets

Reference No.	Country	Status	Application No.	Filing Date	Patent No.	Issue Date	Patent / Application Title	Description
MTEM-002	US	Granted	17/345,576	11-Jun-2021	12,065,469	20-Aug-2024	DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES FOR APPLICATIONS IN MAMMALS	Deimmunized SLT-A with disrupted B- cell epitopes
MTEM-002	US	Pending	18/768,336	10-Jul-2024			DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES FOR APPLICATIONS IN MAMMALS	Deimmunized SLT-A with disrupted B- cell epitopes
MTEM-003	AU	Granted	2015209063	26-Jan-2015	2015209063	15-Aug-2019	MHC CLASS I EPITOPE DELIVERING POLYPEPTIDES	Deimmunized SLT-A with embedded T- cell epitopes
MTEM-003	AU	Granted	2019210656	26-Jan-2015	2019210656	4-Feb-2021	MHC CLASS I EPITOPE DELIVERING POLYPEPTIDES	Deimmunized SLT-A with embedded T- cell epitopes
MTEM-003	AU	Granted	2021200390	26-Jan-2015	2021200390	5-Jan-2023	MHC CLASS I EPITOPE DELIVERING POLYPEPTIDES	Deimmunized SLT-A with embedded T- cell epitopes
MTEM-003	AU	Granted	2022287636	15-Dec-2022	2022287636	18-Apr-2024	MHC CLASS I EPITOPE DELIVERING POLYPEPTIDES	Deimmunized SLT-A with embedded T- cell epitopes
MTEM-003	CA	Allowed	2937395	26-Jan-2015			MHC CLASS I EPITOPE DELIVERING POLYPEPTIDES	Deimmunized SLT-A with embedded T- cell epitopes
MTEM-003	CN	Granted	201580013355.7	26-Jan-2015	106103489	2-Oct-2020	MHC CLASS I EPITOPE DELIVERING POLYPEPTIDES	Deimmunized SLT-A with embedded T- cell epitopes
MTEM-003	CN	Granted	202010812476.0	26-Jan-2015	ZL202010812476.0	9-Apr-2024	MHC CLASS I EPITOPE DELIVERING POLYPEPTIDES	Deimmunized SLT-A with embedded T- cell epitopes
MTEM-003	EP	Granted	15704427.2	26-Jan-2015	3099704	17-Mar-2021	MHC CLASS I EPITOPE DELIVERING POLYPEPTIDES	Deimmunized SLT-A with embedded T- cell epitopes
MTEM-003	EP	Published	21155849.9	31-Mar-2021			MHC CLASS I EPITOPE DELIVERING POLYPEPTIDES	Deimmunized SLT-A with embedded T- cell epitopes
MTEM-003	HK	Granted	16114235.8	14-Dec-2016	1226082	30-Sep-2021	MHC CLASS I EPITOPE DELIVERING POLYPEPTIDES	Deimmunized SLT-A with embedded T- cell epitopes
MTEM-003	HK	Published	42022046552.0	18-Jan-2022			MHC CLASS I EPITOPE DELIVERING POLYPEPTIDES	Deimmunized SLT-A with embedded T- cell epitopes
MTEM-003	IL	Granted	246701	26-Jan-2015	246701	1-Mar-2021	MHC CLASS I EPITOPE DELIVERING POLYPEPTIDES	Deimmunized SLT-A with embedded T- cell epitopes

SCHEDULE AB 60 ATTACHMENT
 Patents, Copyrights, Trademarks, and Trade Secrets

Schedule A/B 60

Patents, copyrights, trademarks, and trade secrets

Reference No.	Country	Status	Application No.	Filing Date	Patent No.	Issue Date	Patent / Application Title	Description
MTEM-003	IL	Granted	278586	26-Jan-2015	278586	1-Dec-2021	MHC CLASS I EPITOPE DELIVERING POLYPEPTIDES	Deimmunized SLT-A with embedded T-cell epitopes
MTEM-003	IL	Granted	285403	26-Jan-2015	285403	2-Sep-2023	MHC CLASS I EPITOPE DELIVERING POLYPEPTIDES	Deimmunized SLT-A with embedded T-cell epitopes
MTEM-003	IL	Allowed	302552	1-May-2023			MHC CLASS I EPITOPE DELIVERING POLYPEPTIDES	Deimmunized SLT-A with embedded T-cell epitopes
MTEM-003	IN	Granted	201617025765	26-Jan-2015	501335	19-Jan-2024	MHC CLASS I EPITOPE DELIVERING POLYPEPTIDES	Deimmunized SLT-A with embedded T-cell epitopes
MTEM-003	JP	Granted	2016-546476	26-Jan-2015	6655017	4-Feb-2020	MHC CLASS I EPITOPE DELIVERING POLYPEPTIDES	Deimmunized SLT-A with embedded T-cell epitopes
MTEM-003	JP	Granted	2021-92504	1-Jun-2021	7229570	17-Feb-2023	MHC CLASS I EPITOPE DELIVERING POLYPEPTIDES	Deimmunized SLT-A with embedded T-cell epitopes
MTEM-003	JP	Granted	2023-016832	7-Feb-2023	7442879	26-Feb-2024	MHC CLASS I EPITOPE DELIVERING POLYPEPTIDES	Deimmunized SLT-A with embedded T-cell epitopes
MTEM-003	KR	Granted	10-2022-7001124	12-Jan-2022	10-2514910	23-Mar-2023	MHC CLASS I EPITOPE DELIVERING POLYPEPTIDES	Deimmunized SLT-A with embedded T-cell epitopes
MTEM-003	KR	Granted	10-2023-7010012	23-Mar-2023	10-2692208	1-Aug-2024	MHC CLASS I EPITOPE DELIVERING POLYPEPTIDES	Deimmunized SLT-A with embedded T-cell epitopes
MTEM-003	MX	Granted	MX/a/2016/009807	26-Jan-2015	382229	4-May-2021	MHC CLASS I EPITOPE DELIVERING POLYPEPTIDES	Deimmunized SLT-A with embedded T-cell epitopes
MTEM-003	MX	Published	MX/a/2021/005131	30-Apr-2021			MHC CLASS I EPITOPE DELIVERING POLYPEPTIDES	Deimmunized SLT-A with embedded T-cell epitopes
MTEM-003	US	Granted	17/231,526	15-Apr-2021	11,312,751	26-Apr-2022	MHC CLASS I EPITOPE DELIVERING POLYPEPTIDES	Deimmunized SLT-A with embedded T-cell epitopes
MTEM-003	US	Granted	17/705,619	28-Mar-2022	12,037,367	16-Jul-2024	MHC CLASS I EPITOPE DELIVERING POLYPEPTIDES	Deimmunized SLT-A with embedded T-cell epitopes
MTEM-003	US	Pending	18/678,030	30-May-2024			MHC CLASS I EPITOPE DELIVERING POLYPEPTIDES	Deimmunized SLT-A with embedded T-cell epitopes

SCHEDULE AB 60 ATTACHMENT
 Patents, Copyrights, Trademarks, and Trade Secrets

Schedule A/B 60

Patents, copyrights, trademarks, and trade secrets

Reference No.	Country	Status	Application No.	Filing Date	Patent No.	Issue Date	Patent / Application Title	Description
MTEM-003	CH	Granted	15704427.2	26-Jan-2015	3099704	17-Mar-2021	MHC CLASS I EPITOPE DELIVERING POLYPEPTIDES	Deimmunized SLT-A with embedded T-cell epitopes
MTEM-003	DE	Granted	15704427.2	26-Jan-2015	3099704	17-Mar-2021	MHC CLASS I EPITOPE DELIVERING POLYPEPTIDES	Deimmunized SLT-A with embedded T-cell epitopes
MTEM-003	ES	Granted	15704427.2	26-Jan-2015	3099704	17-Mar-2021	MHC CLASS I EPITOPE DELIVERING POLYPEPTIDES	Deimmunized SLT-A with embedded T-cell epitopes
MTEM-003	FR	Granted	15704427.2	26-Jan-2015	3099704	17-Mar-2021	MHC CLASS I EPITOPE DELIVERING POLYPEPTIDES	Deimmunized SLT-A with embedded T-cell epitopes
MTEM-003	GB	Granted	15704427.2	26-Jan-2015	3099704	17-Mar-2021	MHC CLASS I EPITOPE DELIVERING POLYPEPTIDES	Deimmunized SLT-A with embedded T-cell epitopes
MTEM-003	IE	Granted	15704427.2	26-Jan-2015	3099704	17-Mar-2021	MHC CLASS I EPITOPE DELIVERING POLYPEPTIDES	Deimmunized SLT-A with embedded T-cell epitopes
MTEM-003	IT	Granted	15704427.2	26-Jan-2015	3099704	17-Mar-2021	MHC CLASS I EPITOPE DELIVERING POLYPEPTIDES	Deimmunized SLT-A with embedded T-cell epitopes
MTEM-003	LI	Granted	15704427.2	26-Jan-2015	3099704	17-Mar-2021	MHC CLASS I EPITOPE DELIVERING POLYPEPTIDES	Deimmunized SLT-A with embedded T-cell epitopes
MTEM-003	NL	Granted	15704427.2	26-Jan-2015	3099704	17-Mar-2021	MHC CLASS I EPITOPE DELIVERING POLYPEPTIDES	Deimmunized SLT-A with embedded T-cell epitopes
MTEM-004	US	Granted	15/117,174	4-Feb-2015	10,421,958	24-Sep-2019	METHODS OF SCREENING, SELECTING, AND IDENTIFYING CYTOTOXIC RECOMBINANT POLYPEPTIDES BASED ON AN INTERIM DIMINUTION OF RIBOTOXICITY	ETB screening method by phage display
MTEM-005	US	Published	17/734,881	2-May-2022			PROTEINS COMPRISING BINDING REGIONS, SHIGA TOXIN A SUBUNIT EFFECTOR REGIONS, AND CARBOXY-TERMINAL, ENDOPLASMIC RETICULUM LOCALIZATION SIGNAL MOTIFS	ETBs having carboxy-terminal ER retention motif

SCHEDULE AB 60 ATTACHMENT

Patents, Copyrights, Trademarks, and Trade Secrets

Schedule A/B 60*Patents, copyrights, trademarks, and trade secrets*

Reference No.	Country	Status	Application No.	Filing Date	Patent No.	Issue Date	Patent / Application Title	Description
MTEM-007	AU	Granted	2015274647	10-Jun-2015	2015274647	23-Jan-2020	PROTEASE-CLEAVAGE RESISTANT, SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES AND CELL-TARGETED MOLECULES COMPRISING THE SAME	Furin-resistant SLT- A
MTEM-007	AU	Granted	2019240612	10-Jun-2015	2019240612	7-Jan-2021	PROTEASE-CLEAVAGE RESISTANT, SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES AND CELL-TARGETED MOLECULES COMPRISING THE SAME	Furin-resistant SLT- A
MTEM-007	AU	Granted	2020260425	10-Jun-2015	2020260425	31-Mar-2022	PROTEASE-CLEAVAGE RESISTANT, SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES AND CELL-TARGETED MOLECULES COMPRISING THE SAME	Furin-resistant SLT- A
MTEM-007	CA	Granted	2947048	10-Jun-2015	2947048	17-Oct-2023	PROTEASE-CLEAVAGE RESISTANT, SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES AND CELL-TARGETED MOLECULES COMPRISING THE SAME	Furin-resistant SLT- A
MTEM-007	CN	Published	202111114179.X	23-Sep-2021			PROTEASE-CLEAVAGE RESISTANT, SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES AND CELL-TARGETED MOLECULES COMPRISING THE SAME	Furin-resistant SLT- A
MTEM-007	EP	Granted	15733018.4	10-Jun-2015	3137488	2-Jan-2019	PROTEASE-CLEAVAGE RESISTANT, SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES AND CELL-TARGETED MOLECULES COMPRISING THE SAME	Furin-resistant SLT- A
MTEM-007	EP	Granted	18207811.3	10-Jun-2015	3514168	1-Sep-2021	PROTEASE-CLEAVAGE RESISTANT, SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES AND CELL-TARGETED MOLECULES COMPRISING THE SAME	Furin-resistant SLT- A

SCHEDULE AB 60 ATTACHMENT

Patents, Copyrights, Trademarks, and Trade Secrets

Schedule A/B 60*Patents, copyrights, trademarks, and trade secrets*

Reference No.	Country	Status	Application No.	Filing Date	Patent No.	Issue Date	Patent / Application Title	Description
MTEM-007	EP	Published	21186953.2	10-Jun-2015			PROTEASE-CLEAVAGE RESISTANT, SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES AND CELL-TARGETED MOLECULES COMPRISING THE SAME	Furin-resistant SLT- A
MTEM-007	IL	Granted	249006	10-Jun-2015	249006	1-Feb-2022	PROTEASE-CLEAVAGE RESISTANT, SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES AND CELL-TARGETED MOLECULES COMPRISING THE SAME	Furin-resistant SLT- A
MTEM-007	IL	Granted	286804	29-Sep-2021	286804	3-Nov-2022	PROTEASE-CLEAVAGE RESISTANT, SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES AND CELL-TARGETED MOLECULES COMPRISING THE SAME	Furin-resistant SLT- A
MTEM-007	IN	Granted	201617042690	10-Jun-2015	429907	25-Apr-2023	PROTEASE-CLEAVAGE RESISTANT, SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES AND CELL-TARGETED MOLECULES COMPRISING THE SAME	Furin-resistant SLT- A
MTEM-007	HK	Granted	17102553.6	13-Mar-2017	1228928	22-Nov-2019	PROTEASE-CLEAVAGE RESISTANT, SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES AND CELL-TARGETED MOLECULES COMPRISING THE SAME	Furin-resistant SLT- A
MTEM-007	HK	Granted	42020001341.5	13-Jan-2020	40011495	11-Mar-2022	PROTEASE-CLEAVAGE RESISTANT, SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES AND CELL-TARGETED MOLECULES COMPRISING THE SAME	Furin-resistant SLT- A
MTEM-007	HK	Published	42022055476.0	20-Jun-2022			PROTEASE-CLEAVAGE RESISTANT, SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES AND CELL-TARGETED MOLECULES COMPRISING THE SAME	Furin-resistant SLT- A

SCHEDULE AB 60 ATTACHMENT

Patents, Copyrights, Trademarks, and Trade Secrets

Schedule A/B 60*Patents, copyrights, trademarks, and trade secrets*

Reference No.	Country	Status	Application No.	Filing Date	Patent No.	Issue Date	Patent / Application Title	Description
MTEM-007	JP	Granted	2016-569950	10-Jun-2015	6735237	15-Jul-2020	PROTEASE-CLEAVAGE RESISTANT, SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES AND CELL-TARGETED MOLECULES COMPRISING THE SAME	Furin-resistant SLT- A
MTEM-007	JP	Granted	2020-120117	10-Jun-2015	7054948	7-Apr-2022	PROTEASE-CLEAVAGE RESISTANT, SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES AND CELL-TARGETED MOLECULES COMPRISING THE SAME	Furin-resistant SLT- A
MTEM-007	KR	Granted	10-2017-7000364	10-Jun-2015	10-2496206	1-Feb-2023	PROTEASE-CLEAVAGE RESISTANT, SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES AND CELL-TARGETED MOLECULES COMPRISING THE SAME	Furin-resistant SLT- A
MTEM-007	MX	Granted	MX/a/2016/016288	10-Jun-2015	373425	22-Jun-2020	PROTEASE-CLEAVAGE RESISTANT, SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES AND CELL-TARGETED MOLECULES COMPRISING THE SAME	Furin-resistant SLT- A
MTEM-007	MX	Pending	MX/a/2020/004420	10-Jun-2015			PROTEASE-CLEAVAGE RESISTANT, SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES AND CELL-TARGETED MOLECULES COMPRISING THE SAME	Furin-resistant SLT- A
MTEM-007	US	Granted	15/317,892	10-Jun-2015	10,815,469	27-Oct-2020	PROTEASE-CLEAVAGE RESISTANT, SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES AND CELL-TARGETED MOLECULES COMPRISING THE SAME	Furin-resistant SLT- A
MTEM-007	CH	Granted	15733018.4	10-Jun-2015	3137488	2-Jan-2019	PROTEASE-CLEAVAGE RESISTANT, SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES AND CELL-TARGETED MOLECULES COMPRISING THE SAME	Furin-resistant SLT- A

SCHEDULE AB 60 ATTACHMENT

Patents, Copyrights, Trademarks, and Trade Secrets

Schedule A/B 60*Patents, copyrights, trademarks, and trade secrets*

Reference No.	Country	Status	Application No.	Filing Date	Patent No.	Issue Date	Patent / Application Title	Description
MTEM-007	DE	Granted	15733018.4	10-Jun-2015	3137488	2-Jan-2019	PROTEASE-CLEAVAGE RESISTANT, SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES AND CELL-TARGETED MOLECULES COMPRISING THE SAME	Furin-resistant SLT- A
MTEM-007	ES	Granted	15733018.4	10-Jun-2015	3137488	2-Jan-2019	PROTEASE-CLEAVAGE RESISTANT, SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES AND CELL-TARGETED MOLECULES COMPRISING THE SAME	Furin-resistant SLT- A
MTEM-007	FR	Granted	15733018.4	10-Jun-2015	3137488	2-Jan-2019	PROTEASE-CLEAVAGE RESISTANT, SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES AND CELL-TARGETED MOLECULES COMPRISING THE SAME	Furin-resistant SLT- A
MTEM-007	GB	Granted	15733018.4	10-Jun-2015	3137488	2-Jan-2019	PROTEASE-CLEAVAGE RESISTANT, SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES AND CELL-TARGETED MOLECULES COMPRISING THE SAME	Furin-resistant SLT- A
MTEM-007	IE	Granted	15733018.4	10-Jun-2015	3137488	2-Jan-2019	PROTEASE-CLEAVAGE RESISTANT, SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES AND CELL-TARGETED MOLECULES COMPRISING THE SAME	Furin-resistant SLT- A
MTEM-007	IT	Granted	502019000013801	10-Jun-2015	3137488	2-Jan-2019	PROTEASE-CLEAVAGE RESISTANT, SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES AND CELL-TARGETED MOLECULES COMPRISING THE SAME	Furin-resistant SLT- A
MTEM-007	LI	Granted	15733018.4	10-Jun-2015	3137488	2-Jan-2019	PROTEASE-CLEAVAGE RESISTANT, SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES AND CELL-TARGETED MOLECULES COMPRISING THE SAME	Furin-resistant SLT- A

SCHEDULE AB 60 ATTACHMENT

Patents, Copyrights, Trademarks, and Trade Secrets

Schedule A/B 60*Patents, copyrights, trademarks, and trade secrets*

Reference No.	Country	Status	Application No.	Filing Date	Patent No.	Issue Date	Patent / Application Title	Description
MTEM-007	NL	Granted	15733018.4	10-Jun-2015	3137488	2-Jan-2019	PROTEASE-CLEAVAGE RESISTANT, SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES AND CELL-TARGETED MOLECULES COMPRISING THE SAME	Furin-resistant SLT- A
MTEM-007	CH	Granted	18207811.3	10-Jun-2015	3514168	1-Sep-2021	PROTEASE-CLEAVAGE RESISTANT, SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES AND CELL-TARGETED MOLECULES COMPRISING THE SAME	Furin-resistant SLT- A
MTEM-007	DE	Granted	18207811.3	10-Jun-2015	3514168	1-Sep-2021	PROTEASE-CLEAVAGE RESISTANT, SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES AND CELL-TARGETED MOLECULES COMPRISING THE SAME	Furin-resistant SLT- A
MTEM-007	ES	Granted	18207811.3	10-Jun-2015	3514168	1-Sep-2021	PROTEASE-CLEAVAGE RESISTANT, SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES AND CELL-TARGETED MOLECULES COMPRISING THE SAME	Furin-resistant SLT- A
MTEM-007	FR	Granted	18207811.3	10-Jun-2015	3514168	1-Sep-2021	PROTEASE-CLEAVAGE RESISTANT, SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES AND CELL-TARGETED MOLECULES COMPRISING THE SAME	Furin-resistant SLT- A
MTEM-007	GB	Granted	18207811.3	10-Jun-2015	3514168	1-Sep-2021	PROTEASE-CLEAVAGE RESISTANT, SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES AND CELL-TARGETED MOLECULES COMPRISING THE SAME	Furin-resistant SLT- A
MTEM-007	IE	Granted	18207811.3	10-Jun-2015	3514168	1-Sep-2021	PROTEASE-CLEAVAGE RESISTANT, SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES AND CELL-TARGETED MOLECULES COMPRISING THE SAME	Furin-resistant SLT- A

SCHEDULE AB 60 ATTACHMENT

Patents, Copyrights, Trademarks, and Trade Secrets

Schedule A/B 60*Patents, copyrights, trademarks, and trade secrets*

Reference No.	Country	Status	Application No.	Filing Date	Patent No.	Issue Date	Patent / Application Title	Description
MTEM-007	IT	Granted	18207811.3	10-Jun-2015	3514168	1-Sep-2021	PROTEASE-CLEAVAGE RESISTANT, SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES AND CELL-TARGETED MOLECULES COMPRISING THE SAME	Furin-resistant SLT- A
MTEM-007	NL	Granted	18207811.3	10-Jun-2015	3514168	1-Sep-2021	PROTEASE-CLEAVAGE RESISTANT, SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES AND CELL-TARGETED MOLECULES COMPRISING THE SAME	Furin-resistant SLT- A
MTEM-008	AU	Granted	2016271124	27-May-2016	2016271124	7-May-2020	DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	AU	Granted	2020201807	27-May-2016	2020201807	16-Dec-2021	DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	AU	Granted	2021240294	1-Oct-2021	2021240294	16-Mar-2023	DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	CA	Published	2984635	27-May-2016			DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	CN	Granted	201680038854.6	27-May-2016	ZL201680038854.6	24-May-2022	DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	CN	Granted	202210426334.X	21-Apr-2022	ZL202210426334.X		DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	EP	Granted	16729701.9	27-May-2016	3303373	8-Apr-2020	DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations

SCHEDULE AB 60 ATTACHMENT

Patents, Copyrights, Trademarks, and Trade Secrets

Schedule A/B 60*Patents, copyrights, trademarks, and trade secrets*

Reference No.	Country	Status	Application No.	Filing Date	Patent No.	Issue Date	Patent / Application Title	Description
MTEM-008	EP	Published	19210151.7	27-May-2016			DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	EP	Published	19212988.0	27-May-2016			DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	HK	Granted	18105551.0	27-May-2016	1246309	15-Jan-2021	DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	HK	Published	42020014715.5	27-May-2016			DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	HK	Published	42020018237.6	16-Oct-2020			DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	IL	Granted	255492	27-May-2016	255492	1-Dec-2021	DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	IL	Granted	285032	21-Jul-2021	285032	2-Sep-2022	DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	IL	Allowed	292708	27-May-2016			DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	IN	Granted	2017/17042736	27-May-2016	422663	22-Feb-2023	DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	JP	Granted	2017-561629	27-May-2016	6771492	1-Oct-2020	DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations

SCHEDULE AB 60 ATTACHMENT
 Patents, Copyrights, Trademarks, and Trade Secrets

Schedule A/B 60*Patents, copyrights, trademarks, and trade secrets*

Reference No.	Country	Status	Application No.	Filing Date	Patent No.	Issue Date	Patent / Application Title	Description
MTEM-008	JP	Granted	2020-163491	27-May-2016	7079522	25-May-2022	DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	JP	Granted	2021-207738	14-Jan-2022	7228931	16-Feb-2023	DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	KR	Granted	10-2017-7037081	27-May-2016	10-2647100	5-Jun-2024	DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	KR	Granted	10-2024-7007951	8-Mar-2024	10-2673972	5-Jun-2024	DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	MX	Granted	MX/a/2017/015493	27-May-2016	382231	4-May-2021	DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	MX	Published	MX/a/2021/005092.	30-Apr-2021			DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	US	Granted	17/233,911	19-Apr-2021	11,365,223	21-Jun-2022	DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	US	Published	17/746,106	17-May-2022			DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	AL	Granted	16729701.9	27-May-2016	3303373	8-Apr-2020	DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	AT	Granted	16729701.9	27-May-2016	3303373	8-Apr-2020	DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations

SCHEDULE AB 60 ATTACHMENT

Patents, Copyrights, Trademarks, and Trade Secrets

Schedule A/B 60*Patents, copyrights, trademarks, and trade secrets*

Reference No.	Country	Status	Application No.	Filing Date	Patent No.	Issue Date	Patent / Application Title	Description
MTEM-008	BE	Granted	16729701.9	27-May-2016	3303373	8-Apr-2020	DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	BG	Granted	16729701.9	27-May-2016	3303373	8-Apr-2020	DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	CH	Granted	16729701.9	27-May-2016	3303373	8-Apr-2020	DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	CY	Granted	16729701.9	27-May-2016	3303373	8-Apr-2020	DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	CZ	Granted	16729701.9	27-May-2016	3303373	8-Apr-2020	DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	DE	Granted	16729701.9	27-May-2016	3303373	8-Apr-2020	DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	DK	Granted	16729701	27-May-2016	3303373	8-Apr-2020	DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	EE	Granted	16729701.9	27-May-2016	3303373	8-Apr-2020	DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	ES	Granted	16729701.9	27-May-2016	3303373	8-Apr-2020	DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	FI	Granted	16729701.9	27-May-2016	3303373	8-Apr-2020	DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations

SCHEDULE AB 60 ATTACHMENT

Patents, Copyrights, Trademarks, and Trade Secrets

Schedule A/B 60*Patents, copyrights, trademarks, and trade secrets*

Reference No.	Country	Status	Application No.	Filing Date	Patent No.	Issue Date	Patent / Application Title	Description
MTEM-008	FR	Granted	16729701.9	27-May-2016	3303373	8-Apr-2020	DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	GB	Granted	16729701.9	27-May-2016	3303373	8-Apr-2020	DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	GR	Granted	16729701.9	27-May-2016	3303373	8-Apr-2020	DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	HR	Granted	16729701.9	27-May-2016	3303373	8-Apr-2020	DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	HU	Granted	16729701.9	27-May-2016	3303373	8-Apr-2020	DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	IE	Granted	16729701.9	27-May-2016	3303373	8-Apr-2020	DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	IS	Granted	16729701.9	27-May-2016	3303373	8-Apr-2020	DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	IT	Granted	502020000040030	27-May-2016	3303373	8-Apr-2020	DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	LI	Granted	16729701.9	27-May-2016	3303373	8-Apr-2020	DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	LT	Granted	16729701.9	27-May-2016	3303373	8-Apr-2020	DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations

SCHEDULE AB 60 ATTACHMENT
 Patents, Copyrights, Trademarks, and Trade Secrets

Schedule A/B 60*Patents, copyrights, trademarks, and trade secrets*

Reference No.	Country	Status	Application No.	Filing Date	Patent No.	Issue Date	Patent / Application Title	Description
MTEM-008	LU	Granted	16729701.9	27-May-2016	3303373	8-Apr-2020	DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	LV	Granted	16729701.9	27-May-2016	3303373	8-Apr-2020	DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	MC	Granted	16729701.9	27-May-2016	3303373	8-Apr-2020	DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	MK	Granted	16729701.9	27-May-2016	3303373	8-Apr-2020	DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	MT	Granted	16729701.9	27-May-2016	3303373	8-Apr-2020	DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	NL	Granted	16729701.9	27-May-2016	3303373	8-Apr-2020	DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	NO	Granted	16729701.9	27-May-2016	3303373	8-Apr-2020	DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	PL	Granted	16729701.9	27-May-2016	3303373	8-Apr-2020	DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	PT	Granted	16729701.9	27-May-2016	3303373	8-Apr-2020	DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	RO	Granted	16729701.9	27-May-2016	3303373	8-Apr-2020	DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations

SCHEDULE AB 60 ATTACHMENT

Patents, Copyrights, Trademarks, and Trade Secrets

Schedule A/B 60*Patents, copyrights, trademarks, and trade secrets*

Reference No.	Country	Status	Application No.	Filing Date	Patent No.	Issue Date	Patent / Application Title	Description
MTEM-008	RS	Granted	16729701.9	27-May-2016	3303373	8-Apr-2020	DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	SE	Granted	16729701.9	27-May-2016	3303373	8-Apr-2020	DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	SI	Granted	16729701.9	27-May-2016	3303373	8-Apr-2020	DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	SK	Granted	16729701.9	27-May-2016	3303373	8-Apr-2020	DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	SM	Granted	16729701.9	27-May-2016	3303373	8-Apr-2020	DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-008	TR	Granted	16729701.9	27-May-2016	3303373	8-Apr-2020	DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME	SLT-A with full complement of deimmunizing mutations
MTEM-009	US	Published	17/459,133	27-Aug-2021			CELL-TARGETING MOLECULES COMPRISING SHIGA TOXIN A SUBUNIT EFFECTORS AND CD8+ T-CELL EPITOPES	ETBs containing C- terminal MHC Class I Epitope (1st generation antigen- seeding technology)
MTEM-010	AU	Granted	2017373962	7-Dec-2017	2017373962	14-Jul-2022	SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES, SHIGA TOXIN EFFECTOR SCAFFOLDS, AND CELL-TARGETING MOLECULES FOR SITE-SPECIFIC CONIUGATION	ETBs containing site-specific conjugation sites
MTEM-010	AU	Granted	2022203538	25-May-2022	2022203538	15-Feb-2024	SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES, SHIGA TOXIN EFFECTOR SCAFFOLDS, AND CELL-TARGETING MOLECULES FOR SITE-SPECIFIC CONIUGATION	ETBs containing site-specific conjugation sites

SCHEDULE AB 60 ATTACHMENT

Patents, Copyrights, Trademarks, and Trade Secrets

Schedule A/B 60*Patents, copyrights, trademarks, and trade secrets*

Reference No.	Country	Status	Application No.	Filing Date	Patent No.	Issue Date	Patent / Application Title	Description
MTEM-010	CA	Published	3043333	7-Dec-2017			SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES, SHIGA TOXIN EFFECTOR SCAFFOLDS, AND CELL-TARGETING MOLECULES FOR SITE-SPECIFIC CONIUGATION	ETBs containing site-specific conjugation sites
MTEM-010	CN	Published	201780085716.8	7-Dec-2017			SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES, SHIGA TOXIN EFFECTOR SCAFFOLDS, AND CELL-TARGETING MOLECULES FOR SITE-SPECIFIC CONIUGATION	ETBs containing site-specific conjugation sites
MTEM-010	CN	Published	202210595624.7	26-May-2022			SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES, SHIGA TOXIN EFFECTOR SCAFFOLDS, AND CELL-TARGETING MOLECULES FOR SITE-SPECIFIC CONIUGATION	ETBs containing site-specific conjugation sites
MTEM-010	EP	Published	17822863.1	7-Dec-2017			SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES, SHIGA TOXIN EFFECTOR SCAFFOLDS, AND CELL-TARGETING MOLECULES FOR SITE-SPECIFIC CONIUGATION	ETBs containing site-specific conjugation sites
MTEM-010	EP	Published	19197879.0	7-Dec-2017			SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES, SHIGA TOXIN EFFECTOR SCAFFOLDS, AND CELL-TARGETING MOLECULES FOR SITE-SPECIFIC CONIUGATION	ETBs containing site-specific conjugation sites
MTEM-010	HK	Published	19131262.8	21-Oct-2019			SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES, SHIGA TOXIN EFFECTOR SCAFFOLDS, AND CELL-TARGETING MOLECULES FOR SITE-SPECIFIC CONIUGATION	ETBs containing site-specific conjugation sites
MTEM-010	HK	Published	42020009700.4	7-Dec-2017			SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES, SHIGA TOXIN EFFECTOR SCAFFOLDS, AND CELL-TARGETING MOLECULES FOR SITE-SPECIFIC CONIUGATION	ETBs containing site-specific conjugation sites

SCHEDULE AB 60 ATTACHMENT

Patents, Copyrights, Trademarks, and Trade Secrets

Schedule A/B 60*Patents, copyrights, trademarks, and trade secrets*

Reference No.	Country	Status	Application No.	Filing Date	Patent No.	Issue Date	Patent / Application Title	Description
MTEM-010	IL	Granted	266583	7-Dec-2017	266583	2-Aug-2023	SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES, SHIGA TOXIN EFFECTOR SCAFFOLDS, AND CELL-TARGETING MOLECULES FOR SITE-SPECIFIC CONIUGATION	ETBs containing site-specific conjugation sites
MTEM-010	IL	Allowed	293710	8-Jun-2022			SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES, SHIGA TOXIN EFFECTOR SCAFFOLDS, AND CELL-TARGETING MOLECULES FOR SITE-SPECIFIC CONIUGATION	ETBs containing site-specific conjugation sites
MTEM-010	IN	Published	201917022536	7-Dec-2017			SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES, SHIGA TOXIN EFFECTOR SCAFFOLDS, AND CELL-TARGETING MOLECULES FOR SITE-SPECIFIC CONIUGATION	ETBs containing site-specific conjugation sites
MTEM-010	JP	Granted	2019-528111	7-Dec-2017	7075134	17-May-2022	SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES, SHIGA TOXIN EFFECTOR SCAFFOLDS, AND CELL-TARGETING MOLECULES FOR SITE-SPECIFIC CONIUGATION	ETBs containing site-specific conjugation sites
MTEM-010	JP	Granted	2022-076399	6-May-2022	7370625	20-Oct-2023	SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES, SHIGA TOXIN EFFECTOR SCAFFOLDS, AND CELL-TARGETING MOLECULES FOR SITE-SPECIFIC CONIUGATION	ETBs containing site-specific conjugation sites
MTEM-010	KR	Granted	10-2019-7019157	7-Dec-2017	10-2580647	15-Sep-2023	SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES, SHIGA TOXIN EFFECTOR SCAFFOLDS, AND CELL-TARGETING MOLECULES FOR SITE-SPECIFIC CONIUGATION	ETBs containing site-specific conjugation sites
MTEM-010	KR	Granted	10-2022-7016919	19-May-2022	10-2557126	14-Jul-2023	SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES, SHIGA TOXIN EFFECTOR SCAFFOLDS, AND CELL-TARGETING MOLECULES FOR SITE-SPECIFIC CONIUGATION	ETBs containing site-specific conjugation sites

SCHEDULE AB 60 ATTACHMENT

Patents, Copyrights, Trademarks, and Trade Secrets

Schedule A/B 60*Patents, copyrights, trademarks, and trade secrets*

Reference No.	Country	Status	Application No.	Filing Date	Patent No.	Issue Date	Patent / Application Title	Description
MTEM-010	MX	Granted	MX/a/2019/006656	7-Dec-2017	410543	15-Feb-2024	SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES, SHIGA TOXIN EFFECTOR SCAFFOLDS, AND CELL-TARGETING MOLECULES FOR SITE-SPECIFIC CONIUGATION	ETBs containing site-specific conjugation sites
MTEM-010	MX	Published	MX/a/2022/006511	16-May-2022			SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES, SHIGA TOXIN EFFECTOR SCAFFOLDS, AND CELL-TARGETING MOLECULES FOR SITE-SPECIFIC CONIUGATION	ETBs containing site-specific conjugation sites
MTEM-010	US	Granted	17/314,563	7-May-2021	11,389,542	19-Jul-2022	SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES, SHIGA TOXIN EFFECTOR SCAFFOLDS, AND CELL-TARGETING MOLECULES FOR SITE-SPECIFIC CONIUGATION	ETBs containing site-specific conjugation sites
MTEM-010	US	Granted	17/533,552	23-Nov-2021	11,857,628	2-Jan-2024	SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES, SHIGA TOXIN EFFECTOR SCAFFOLDS, AND CELL-TARGETING MOLECULES FOR SITE-SPECIFIC CONIUGATION	ETBs containing site-specific conjugation sites
MTEM-010	US	Pending	18/507,264	13-Nov-2023			SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES, SHIGA TOXIN EFFECTOR SCAFFOLDS, AND CELL-TARGETING MOLECULES FOR SITE-SPECIFIC CONIUGATION	ETBs containing site-specific conjugation sites
MTEM-011	AU	Granted	2018213194	24-Jan-2018	2018213194	27-Apr-2023	CELL-TARGETING MOLECULES COMPRISING DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT EFFECTORS AND CD8+ T-CELL EPITOPES	ETBs containing C- terminal MHC Class I Epitope (2nd generation antigen- seeding technology)
MTEM-011	CA	Published	3049456	24-Jan-2018			CELL-TARGETING MOLECULES COMPRISING DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT EFFECTORS AND CD8+ T-CELL EPITOPES	ETBs containing C- terminal MHC Class I Epitope (2nd generation antigen- seeding technology)

SCHEDULE AB 60 ATTACHMENT

Patents, Copyrights, Trademarks, and Trade Secrets

Schedule A/B 60*Patents, copyrights, trademarks, and trade secrets*

Reference No.	Country	Status	Application No.	Filing Date	Patent No.	Issue Date	Patent / Application Title	Description
MTEM-011	CN	Granted	201880021212.4	24-Jan-2018	ZL201880021212.4	10-May-2024	CELL-TARGETING MOLECULES COMPRISING DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT EFFECTORS AND CD8+ T-CELL EPITOPES	ETBs containing C- terminal MHC Class I Epitope (2nd generation antigen- seeding technology)
MTEM-011	EP	Granted	18708500.6	24-Jan-2018	3573648B1	22-Nov-2023	CELL-TARGETING MOLECULES COMPRISING DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT EFFECTORS AND CD8+ T-CELL EPITOPES	ETBs containing C- terminal MHC Class I Epitope (2nd generation antigen- seeding technology)
MTEM-011	HK	Granted	62020002656.0	24-Jan-2018	40013269	22-Nov-2023	CELL-TARGETING MOLECULES COMPRISING DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT EFFECTORS AND CD8+ T-CELL EPITOPES	ETBs containing C- terminal MHC Class I Epitope (2nd generation antigen- seeding technology)
MTEM-011	IL	Granted	267990	24-Jan-2018	267990	4-Mar-2024	CELL-TARGETING MOLECULES COMPRISING DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT EFFECTORS AND CD8+ T-CELL EPITOPES	ETBs containing C- terminal MHC Class I Epitope (2nd generation antigen- seeding technology)
MTEM-011	JP	Granted	2019-537765	24-Jan-2018	7082424	31-May-2022	CELL-TARGETING MOLECULES COMPRISING DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT EFFECTORS AND CD8+ T-CELL EPITOPES	ETBs containing C- terminal MHC Class I Epitope (2nd generation antigen- seeding technology)
MTEM-011	KR	Granted	10-2019-7024623	24-Jan-2018	10-2590672	13-Oct-2023	CELL-TARGETING MOLECULES COMPRISING DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT EFFECTORS AND CD8+ T-CELL EPITOPES	ETBs containing C- terminal MHC Class I Epitope (2nd generation antigen- seeding technology)
MTEM-011	MX	Granted	MX/a/2019/008840	24-Jan-2018	415694		CELL-TARGETING MOLECULES COMPRISING DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT EFFECTORS AND CD8+ T-CELL EPITOPES	ETBs containing C- terminal MHC Class I Epitope (2nd generation antigen- seeding technology)
MTEM-011	US	Granted	17/228,579	12-Apr-2021	11,406,692	9-Aug-2022	CELL-TARGETING MOLECULES COMPRISING DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT EFFECTORS AND CD8+ T-CELL EPITOPES	ETBs containing C- terminal MHC Class I Epitope (2nd generation antigen- seeding technology)

SCHEDULE AB 60 ATTACHMENT

Patents, Copyrights, Trademarks, and Trade Secrets

Schedule A/B 60*Patents, copyrights, trademarks, and trade secrets*

Reference No.	Country	Status	Application No.	Filing Date	Patent No.	Issue Date	Patent / Application Title	Description
MTEM-011	US	Published	17/852,669	29-Jun-2022			CELL-TARGETING MOLECULES COMPRISING DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT EFFECTORS AND CD8+ T-CELL EPITOPES	ETBs containing C- terminal MHC Class I Epitope (2nd generation antigen- seeding technology)
MTEM-011	DE	Granted	18708500.6	24-Jan-2018	3573648	22-Nov-2023	CELL-TARGETING MOLECULES COMPRISING DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT EFFECTORS AND CD8+ T-CELL EPITOPES	ETBs containing C- terminal MHC Class I Epitope (2nd generation antigen- seeding technology)
MTEM-011	ES	Granted	18708500.6	24-Jan-2018	3573648	22-Nov-2023	CELL-TARGETING MOLECULES COMPRISING DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT EFFECTORS AND CD8+ T-CELL EPITOPES	ETBs containing C- terminal MHC Class I Epitope (2nd generation antigen- seeding technology)
MTEM-011	FR	Granted	18708500.6	24-Jan-2018	3573648	22-Nov-2023	CELL-TARGETING MOLECULES COMPRISING DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT EFFECTORS AND CD8+ T-CELL EPITOPES	ETBs containing C- terminal MHC Class I Epitope (2nd generation antigen- seeding technology)
MTEM-011	GB	Granted	18708500.6	24-Jan-2018	3573648	22-Nov-2023	CELL-TARGETING MOLECULES COMPRISING DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT EFFECTORS AND CD8+ T-CELL EPITOPES	ETBs containing C- terminal MHC Class I Epitope (2nd generation antigen- seeding technology)
MTEM-011	IE	Granted	18708500.6	24-Jan-2018	3573648	22-Nov-2023	CELL-TARGETING MOLECULES COMPRISING DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT EFFECTORS AND CD8+ T-CELL EPITOPES	ETBs containing C- terminal MHC Class I Epitope (2nd generation antigen- seeding technology)
MTEM-011	IT	Granted	18708500.6	24-Jan-2018	3573648	22-Nov-2023	CELL-TARGETING MOLECULES COMPRISING DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT EFFECTORS AND CD8+ T-CELL EPITOPES	ETBs containing C- terminal MHC Class I Epitope (2nd generation antigen- seeding technology)
MTEM-100.01	US	Granted	14/774,609	11-Mar-2014	10,450,354	22-Oct-2019	CD20-BINDING IMMUNOTOXINS FOR INDUCING CELLULAR INTERNALIZATION AND METHODS USING SAME	CD20 Binding ETBs
MTEM-100.01	US	Granted	14/643,619	10-Mar-2015	11,142,584	12-Oct-2021	CD20-BINDING IMMUNOTOXINS FOR INDUCING CELLULAR INTERNALIZATION AND METHODS USING SAME	CD20 Binding ETBs

SCHEDULE AB 60 ATTACHMENT

Patents, Copyrights, Trademarks, and Trade Secrets

Schedule A/B 60*Patents, copyrights, trademarks, and trade secrets*

Reference No.	Country	Status	Application No.	Filing Date	Patent No.	Issue Date	Patent / Application Title	Description
MTEM-100.02	US	Granted	15/549,099	4-Feb-2016	10,392,425	27-Aug-2019	MULTIVALENT CD20-BINDING MOLECULES COMPRISING SHIGA TOXIN A SUBUNIT EFFECTOR REGIONS AND ENRICHED COMPOSITIONS THEREOF	Dimeric CD20 Binding ETBs
MTEM-100.02	US	Granted	15/290,266	4-Feb-2016	11,248,061	15-Feb-2022	MULTIVALENT CD20-BINDING MOLECULES COMPRISING SHIGA TOXIN A SUBUNIT EFFECTOR REGIONS AND ENRICHED COMPOSITIONS THEREOF	Dimeric CD20 Binding ETBs
MTEM-100.02	US	Granted	16/515,829	18-Jul-2019	11,104,707	31-Aug-2021	MULTIVALENT CD20-BINDING MOLECULES COMPRISING SHIGA TOXIN A SUBUNIT EFFECTOR REGIONS AND ENRICHED COMPOSITIONS THEREOF	Dimeric CD20 Binding ETBs
MTEM-100.02	HK	Granted	18100353.1	4-Feb-2016	1240950	9-Apr-2021	MULTIVALENT CD20-BINDING MOLECULES COMPRISING SHIGA TOXIN A SUBUNIT EFFECTOR REGIONS AND ENRICHED COMPOSITIONS THEREOF	Dimeric CD20 Binding ETBs
MTEM-200.01	AU	Pending	2019257343	16-Apr-2019			HER2-TARGETING MOLECULES COMPRISING DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS	HER2 Binding ETBs
MTEM-200.01	CA	Published	3097178	16-Apr-2019			HER2-TARGETING MOLECULES COMPRISING DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS	HER2 Binding ETBs
MTEM-200.01	CN	Granted	201980001414.7	16-Apr-2019	ZL201980001414.7	12-Apr-2024	HER2-TARGETING MOLECULES COMPRISING DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS	HER2 Binding ETBs
MTEM-200.01	EP	Published	19720329.2	16-Apr-2019			HER2-TARGETING MOLECULES COMPRISING DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS	HER2 Binding ETBs
MTEM-200.01	HK	Published	62020003186.7	16-Apr-2019			HER2-TARGETING MOLECULES COMPRISING DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS	HER2 Binding ETBs

SCHEDULE AB 60 ATTACHMENT

Patents, Copyrights, Trademarks, and Trade Secrets

Schedule A/B 60*Patents, copyrights, trademarks, and trade secrets*

Reference No.	Country	Status	Application No.	Filing Date	Patent No.	Issue Date	Patent / Application Title	Description
MTEM-200.01	IL	Granted	268443	16-Apr-2019	268443	3-Jun-2024	HER2-TARGETING MOLECULES COMPRISING DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS	HER2 Binding ETBs
MTEM-200.01	JP	Granted	2020-554502	16-Apr-2019	7323200	31-Jul-2023	HER2-TARGETING MOLECULES COMPRISING DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS	HER2 Binding ETBs
MTEM-200.01	KR	Published	10-2019-7024980	16-Apr-2019			HER2-TARGETING MOLECULES COMPRISING DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS	HER2 Binding ETBs
MTEM-200.01	MX	Pending	MX/a/2019/009726	16-Apr-2019			HER2-TARGETING MOLECULES COMPRISING DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS	HER2 Binding ETBs
MTEM-200.01	US	Granted	17/072,562	16-Oct-2020	11,225,509	18-Jan-2022	HER2-TARGETING MOLECULES COMPRISING DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS	HER2 Binding ETBs
MTEM-200.02	US	Pending	18/006,216	20-Jan-2023			CLINICAL METHODS FOR USE OF HER2 BINDING MOLECULES	Methods of Treating Cancer with HER2 Binding ETBs
MTEM-301.01	AU	Pending	2020348861	21-Dec-2021			PD-L1-BINDING MOLECULES COMPRISING SHIGA TOXIN A SUBUNIT SCAFFOLDS	PD-L1 Binding ETBs
MTEM-301.01	CA	Pending	3149621	1-Feb-2022			PD-L1-BINDING MOLECULES COMPRISING SHIGA TOXIN A SUBUNIT SCAFFOLDS	PD-L1 Binding ETBs
MTEM-301.01	CN	Published	202080065242.2	17-Mar-2022			PD-L1-BINDING MOLECULES COMPRISING SHIGA TOXIN A SUBUNIT SCAFFOLDS	PD-L1 Binding ETBs
MTEM-301.01	EP	Published	20786366.3	18-Sep-2020			PD-L1-BINDING MOLECULES COMPRISING SHIGA TOXIN A SUBUNIT SCAFFOLDS	PD-L1 Binding ETBs
MTEM-301.01	HK	Published	62022058149.5	9-Aug-2022			PD-L1-BINDING MOLECULES COMPRISING SHIGA TOXIN A SUBUNIT SCAFFOLDS	PD-L1 Binding ETBs

SCHEDULE AB 60 ATTACHMENT
Patents, Copyrights, Trademarks, and Trade Secrets

Schedule A/B 60

Patents, copyrights, trademarks, and trade secrets

Reference No.	Country	Status	Application No.	Filing Date	Patent No.	Issue Date	Patent / Application Title	Description
MTEM-301.01	IL	Pending	291402	18-Sep-2020			PD-L1-BINDING MOLECULES COMPRISING SHIGA TOXIN A SUBUNIT SCAFFOLDS	PD-L1 Binding ETBs
MTEM-301.01	IN	Published	202217015563	21-Mar-2022			PD-L1-BINDING MOLECULES COMPRISING SHIGA TOXIN A SUBUNIT SCAFFOLDS	PD-L1 Binding ETBs
MTEM-301.01	JP	Published	JP2022-516301	14-Mar-2022			PD-L1-BINDING MOLECULES COMPRISING SHIGA TOXIN A SUBUNIT SCAFFOLDS	PD-L1 Binding ETBs
MTEM-301.01	KR	Published	10-2022-7008153	11-Mar-2022			PD-L1-BINDING MOLECULES COMPRISING SHIGA TOXIN A SUBUNIT SCAFFOLDS	PD-L1 Binding ETBs
MTEM-301.01	MX	Published	MX/a/2022/003195	15-Mar-2022			PD-L1-BINDING MOLECULES COMPRISING SHIGA TOXIN A SUBUNIT SCAFFOLDS	PD-L1 Binding ETBs
MTEM-301.01	US	Granted	17/025,729	18-Sep-2020	11,918,649	5-Mar-2024	PD-L1-BINDING MOLECULES COMPRISING SHIGA TOXIN A SUBUNIT SCAFFOLDS	PD-L1 Binding ETBs
MTEM-301.01	US	Granted	17/027,120	18-Sep-2020	11,136,395	5-Oct-2021	PD-L1-BINDING MOLECULES COMPRISING SHIGA TOXIN A SUBUNIT SCAFFOLDS	PD-L1 Binding ETBs
MTEM-301.01	US	Pending	18/425,310	18-Sep-2020			PD-L1-BINDING MOLECULES COMPRISING SHIGA TOXIN A SUBUNIT SCAFFOLDS	PD-L1 Binding ETBs
MTEM-301.02	US	Published	17/553,333	16-Dec-2021			CLINICAL METHODS FOR USE OF A PD- L1- BINDING MOLECULE COMPRISING A SHIGA TOXIN EFFECTOR	Methods of Treating Cancer with PD- L1 Binding ETBs
MTEM-301.02	EP	Pending	21841152.8	13-Jul-2023			CLINICAL METHODS FOR USE OF A PD- L1- BINDING MOLECULE COMPRISING A SHIGA TOXIN EFFECTOR	Methods of Treating Cancer with PD- L1 Binding ETBs
MTEM-301.02	WO	Published	PCT/US2021/063817	16-Dec-2021			CLINICAL METHODS FOR USE OF A PD- L1- BINDING MOLECULE COMPRISING A SHIGA TOXIN EFFECTOR	Methods of Treating Cancer with PD- L1 Binding ETBs

SCHEDULE AB 60 ATTACHMENT

Patents, Copyrights, Trademarks, and Trade Secrets

Schedule A/B 60*Patents, copyrights, trademarks, and trade secrets*

Reference No.	Country	Status	Application No.	Filing Date	Patent No.	Issue Date	Patent / Application Title	Description
MTEM-301.03	WO	Published	PCT/US2022/020781	17-Mar-2022			PD-L1 BINDING PROTEINS COMPRISING SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CD8+ T CELL ANTIGENS	PD-L1 Binding ETBs Targeting Alternative HLA Subtypes
MTEM-301.03	CA	Pending	3,213,295	17-Mar-2022			PD-L1 BINDING PROTEINS COMPRISING SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CD8+ T CELL ANTIGENS	PD-L1 Binding ETBs Targeting Alternative HLA Subtypes
MTEM-301.03	EP	Pending	22714730.3	17-Mar-2022			PD-L1 BINDING PROTEINS COMPRISING SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CD8+ T CELL ANTIGENS	PD-L1 Binding ETBs Targeting Alternative HLA Subtypes
MTEM-301.03	US	Published	17/697,564	17-Mar-2022			PD-L1 BINDING PROTEINS COMPRISING SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CD8+ T CELL ANTIGENS	PD-L1 Binding ETBs Targeting Alternative HLA Subtypes
MTEM-400.01	LB	Granted	223	23-Jan-2020	11845	23-Jan-2020	CD38-BINDING PROTEINS COMPRISING DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTORS	CD38 Binding ETBs
MTEM-400.01	AU	Pending	2020213103	23-Jan-2020			CD38-BINDING PROTEINS COMPRISING DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTORS	CD38 Binding ETBs
MTEM-400.01	CA	Published	3127660	17-Aug-2021			CD38-BINDING PROTEINS COMPRISING DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTORS	CD38 Binding ETBs
MTEM-400.01	CN	Published	202080010483.7	13-Aug-2021			CD38-BINDING PROTEINS COMPRISING DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTORS	CD38 Binding ETBs
MTEM-400.01	EP	Published	20708310.6	23-Jan-2020			CD38-BINDING PROTEINS COMPRISING DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTORS	CD38 Binding ETBs
MTEM-400.01	HK	Pending	62021044698.0	16-Dec-2021			CD38-BINDING PROTEINS COMPRISING DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTORS	CD38 Binding ETBs

SCHEDULE AB 60 ATTACHMENT
Patents, Copyrights, Trademarks, and Trade Secrets

Schedule A/B 60*Patents, copyrights, trademarks, and trade secrets*

Reference No.	Country	Status	Application No.	Filing Date	Patent No.	Issue Date	Patent / Application Title	Description
MTEM-400.01	IL	Pending	284810	23-Jan-2020			CD38-BINDING PROTEINS COMPRISING DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTORS	CD38 Binding ETBs
MTEM-400.01	IN	Published	202117032477	19-Jul-2021			CD38-BINDING PROTEINS COMPRISING DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTORS	CD38 Binding ETBs
MTEM-400.01	JP	Granted	2021-541634	19-Jul-2021	7418756	12-Jan-2024	CD38-BINDING PROTEINS COMPRISING DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTORS	CD38 Binding ETBs
MTEM-400.01	KR	Published	10-2021-7024877	5-Aug-2021			CD38-BINDING PROTEINS COMPRISING DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTORS	CD38 Binding ETBs
MTEM-400.01	MX	Published	MX/a/2021/008790	21-Jul-2021			CD38-BINDING PROTEINS COMPRISING DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTORS	CD38 Binding ETBs
MTEM-400.01	US	Granted	16/751,144	23-Jan-2020	11,713,347	1-Aug-2023	CD38-BINDING PROTEINS COMPRISING DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTORS	CD38 Binding ETBs
MTEM-400.01	US	Allowed	18/332,366	9-Jun-2023			CD38-BINDING PROTEINS COMPRISING DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTORS	CD38 Binding ETBs
MTEM-501.01	US	Pending	18/180,785	8-Mar-2023			CTLA-4 BINDING MOLECULES COMPRISING SHIGA TOXIN A SUBUNIT, SCAFFOLDS AND USES THEREOF	CTLA-4 Binding ETBs
MTEM-501.01	WO	Pending	PCT/US2023/063988	8-Mar-2023			CTLA-4 BINDING MOLECULES COMPRISING SHIGA TOXIN A SUBUNIT, SCAFFOLDS AND USES THEREOF	CTLA-4 Binding ETBs
THRSD-0001	US	Granted	13/658,741	23-Oct-2012	9,205,098	8-Dec-2015	Anti-Cancer Therapies	Hypoxia-activated prodrugs such as glufosfamide

SCHEDULE AB 60 ATTACHMENT
 Patents, Copyrights, Trademarks, and Trade Secrets

Schedule A/B 60

Patents, copyrights, trademarks, and trade secrets

Reference No.	Country	Status	Application No.	Filing Date	Patent No.	Issue Date	Patent / Application Title	Description
THRSD-0001	US	Granted	10/546,612	18-Aug-2005	7,560,230	14-Jul-2009	METHOD FOR DETERMINING SUSCEPTIBILITY OF TUMOR TO TREATMENT WITH ANTI-NEOPLASTIC AGENT	Hypoxia-activated prodrugs such as glufosfamide
THRSD-0001	US	Granted	12/992,261	28-Mar-2011	8,309,554	13-Nov-2012	HYPOXIA ACTIVATED DRUGS OF NITROGEN MUSTARD ALKYLATORS	Hypoxia-activated prodrugs such as glufosfamide
THRSD-0001	EP	Granted	055712714	4-Feb-2005	1711188	6-Jun-2012	ANTI-CANCER THERAPIES\$KREBSTERAPIEN\$THERAPIES ANTICANCEREUSES	Hypoxia-activated prodrugs such as glufosfamide
THRSD-0001	DK	Granted	055712714	4-Feb-2005	1711188	6-Jun-2012	ANTI-CANCER THERAPIES\$KREBSTERAPIEN\$THERAPIES ANTICANCEREUSES	Hypoxia-activated prodrugs such as glufosfamide
THRSD-0001	ES	Granted	055712714	4-Feb-2005	1711188	6-Jun-2012	ANTI-CANCER THERAPIES\$KREBSTERAPIEN\$THERAPIES ANTICANCEREUSES	Hypoxia-activated prodrugs such as glufosfamide
THRSD-0001	FR	Granted	055712714	4-Feb-2005	1711188	6-Jun-2012	ANTI-CANCER THERAPIES\$KREBSTERAPIEN\$THERAPIES ANTICANCEREUSES	Hypoxia-activated prodrugs such as glufosfamide
THRSD-0001	GB	Granted	055712714	4-Feb-2005	1711188	6-Jun-2012	ANTI-CANCER THERAPIES\$KREBSTERAPIEN\$THERAPIES ANTICANCEREUSES	Hypoxia-activated prodrugs such as glufosfamide
THRSD-0001	IT	Granted	055712714	4-Feb-2005	1711188	6-Jun-2012	ANTI-CANCER THERAPIES\$KREBSTERAPIEN\$THERAPIES ANTICANCEREUSES	Hypoxia-activated prodrugs such as glufosfamide
THRSD-0001	LI	Granted	055712714	4-Feb-2005	1711188	6-Jun-2012	ANTI-CANCER THERAPIES\$KREBSTERAPIEN\$THERAPIES ANTICANCEREUSES	Hypoxia-activated prodrugs such as glufosfamide
THRSD-0001	LT	Granted	055712714	4-Feb-2005	1711188	6-Jun-2012	ANTI-CANCER THERAPIES\$KREBSTERAPIEN\$THERAPIES ANTICANCEREUSES	Hypoxia-activated prodrugs such as glufosfamide

SCHEDULE AB 60 ATTACHMENT
 Patents, Copyrights, Trademarks, and Trade Secrets

Schedule A/B 60*Patents, copyrights, trademarks, and trade secrets*

Reference No.	Country	Status	Application No.	Filing Date	Patent No.	Issue Date	Patent / Application Title	Description
THRSD-0001	NL	Granted	055712714	4-Feb-2005	1711188	6-Jun-2012	ANTI-CANCER THERAPIES\$KREBSTERAPIEN\$THERA PIES ANTICANCEREUSES	Hypoxia-activated prodrugs such as glufosfamide
THRSD-0001	SE	Granted	055712714	4-Feb-2005	1711188	6-Jun-2012	ANTI-CANCER THERAPIES\$KREBSTERAPIEN\$THERA PIES ANTICANCEREUSES	Hypoxia-activated prodrugs such as glufosfamide
THRSD-0001	DE	Granted	055712714	4-Feb-2005	1711188	6-Jun-2012	ANTI-CANCER THERAPIES\$KREBSTERAPIEN\$THERA PIES ANTICANCEREUSES	Hypoxia-activated prodrugs such as glufosfamide
THRSD-0001	IE	Granted	055712714	4-Feb-2005	1711188	6-Jun-2012	ANTI-CANCER THERAPIES\$KREBSTERAPIEN\$THERA PIES ANTICANCEREUSES	Hypoxia-activated prodrugs such as glufosfamide
THRSD-0001	CH	Granted	055712714	4-Feb-2005	1711188	6-Jun-2012	ANTI-CANCER THERAPIES\$KREBSTERAPIEN\$THERA PIES ANTICANCEREUSES	Hypoxia-activated prodrugs such as glufosfamide
THRSD-0001	LU	Granted	055712714	4-Feb-2005	1711188	6-Jun-2012	ANTI-CANCER THERAPIES\$KREBSTERAPIEN\$THERA PIES ANTICANCEREUSES	Hypoxia-activated prodrugs such as glufosfamide
THRSD-0001	CN	Granted	201080036229.0	10-Jun-2010	102574866	18-Feb-2015	Camptothecin derivatives	Hypoxia-activated prodrugs such as glufosfamide
THRSD-0001	JP	Granted	2006552230	4-Feb-2005	5235304	5-Apr-2013	Anticancer Therapy	Hypoxia-activated prodrugs such as glufosfamide
THRSD-0002	US	Granted	12/594,802	7-Apr-2008	8765690	7-Jul-2014	Treatment of cancer with glufosfamide in patients not receiving insulin therapy	Hypoxia-activated prodrugs such as glufosfamide
THRSD-0003	US	Granted	13/378,662	16-Jun-2010	8,575,188	5-Nov-2013	Camptothecin derivatives	Hypoxia-activated prodrugs such as glufosfamide

Fill in this information to identify the case:Debtor name **Molecular Templates Opco, Inc.**United States Bankruptcy Court for the: **DISTRICT OF DELAWARE**Case number (if known) **25-10740**☐ Check if this is an amended filing**Official Form 206D****Schedule D: Creditors Who Have Claims Secured by Property****12/15**

Be as complete and accurate as possible.

1. Do any creditors have claims secured by debtor's property?

- ☐ No. Check this box and submit page 1 of this form to the court with debtor's other schedules. Debtor has nothing else to report on this form.
- ☒ Yes. Fill in all of the information below.

Part 1: List Creditors Who Have Secured Claims

2. List in alphabetical order all creditors who have secured claims. If a creditor has more than one secured claim, list the creditor separately for each claim.

		Column A Amount of claim Do not deduct the value of collateral.	Column B Value of collateral that supports this claim	
2.1	K2 HealthVentures LLC <small>Creditor's Name</small> c/o Ankura Trust Company, LLC 140 Sherman Steet 4th Floor Fairfield, CT 06824 <small>Creditor's mailing address</small> jeri.miller@sidley.com <small>Creditor's email address, if known</small> Date debt was incurred 2/1/2026 Last 4 digits of account number Do multiple creditors have an interest in the same property? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes. Specify each creditor, including this creditor and its relative priority.	Describe debtor's property that is subject to a lien Substantially all assets Describe the lien Amended & Restated CVR Agreement Is the creditor an insider or related party? <input type="checkbox"/> No <input checked="" type="checkbox"/> Yes Is anyone else liable on this claim? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes. Fill out <i>Schedule H: Codebtors</i> (Official Form 206H) As of the petition filing date, the claim is: Check all that apply <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed	\$24,300,515.15	Unknown

2.2	K2 HealthVentures LLC <small>Creditor's Name</small> c/o Ankura Trust Company, LLC 140 Sherman Steet 4th Floor Fairfield, CT 06824 <small>Creditor's mailing address</small> jeri.miller@sidley.com <small>Creditor's email address, if known</small> Date debt was incurred 6/16/2023	Describe debtor's property that is subject to a lien Substantially all assets Describe the lien Prepetition Bridge Loan Is the creditor an insider or related party? <input type="checkbox"/> No <input checked="" type="checkbox"/> Yes Is anyone else liable on this claim? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes. Fill out <i>Schedule H: Codebtors</i> (Official Form 206H)	\$1,366,231.92	Unknown
------------	--	--	-----------------------	----------------

Debtor **Molecular Templates Opco, Inc.**

Name

Case number (if known)

25-10740

Last 4 digits of account number

Do multiple creditors have an interest in the same property?

☒ No☐ Yes. Specify each creditor, including this creditor and its relative priority.

As of the petition filing date, the claim is:

Check all that apply

☐ Contingent☐ Unliquidated☐ Disputed

3. Total of the dollar amounts from Part 1, Column A, including the amounts from the Additional Page, if any.

**\$25,666,747.
07****Part 2: List Others to Be Notified for a Debt Already Listed in Part 1**

List in alphabetical order any others who must be notified for a debt already listed in Part 1. Examples of entities that may be listed are collection agencies, assignees of claims listed above, and attorneys for secured creditors.

If no others need to be notified for the debts listed in Part 1, do not fill out or submit this page. If additional pages are needed, copy this page.

Name and address

On which line in Part 1 did you enter the related creditor?

Last 4 digits of account number for this entity

Fill in this information to identify the case:Debtor name **Molecular Templates Opco, Inc.**United States Bankruptcy Court for the: **DISTRICT OF DELAWARE**Case number (if known) **25-10740**☐ Check if this is an amended filing**Official Form 206E/F****Schedule E/F: Creditors Who Have Unsecured Claims****12/15**

Be as complete and accurate as possible. Use Part 1 for creditors with PRIORITY unsecured claims and Part 2 for creditors with NONPRIORITY unsecured claims. List the other party to any executory contracts or unexpired leases that could result in a claim. Also list executory contracts on *Schedule A/B: Assets - Real and Personal Property* (Official Form 206A/B) and on *Schedule G: Executory Contracts and Unexpired Leases* (Official Form 206G). Number the entries in Parts 1 and 2 in the boxes on the left. If more space is needed for Part 1 or Part 2, fill out and attach the Additional Page of that Part included in this form.

Part 1: List All Creditors with PRIORITY Unsecured Claims**1. Do any creditors have priority unsecured claims?** (See 11 U.S.C. § 507).☐ No. Go to Part 2.☒ Yes. Go to line 2.**2. List in alphabetical order all creditors who have unsecured claims that are entitled to priority in whole or in part.** If the debtor has more than 3 creditors with priority unsecured claims, fill out and attach the Additional Page of Part 1.

			Total claim	Priority amount
2.1	Priority creditor's name and mailing address Internal Revenue Service Department of Treasury Cincinnati, OH 45999-0038	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input checked="" type="checkbox"/> Contingent <input checked="" type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed	Unknown	Unknown
	Date or dates debt was incurred Last 4 digits of account number Specify Code subsection of PRIORITY unsecured claim: 11 U.S.C. § 507(a) (8)	Basis for the claim: Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes		
2.2	Priority creditor's name and mailing address Texas Comptroller PO Box 149348 Austin, TX 78714-9348	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input checked="" type="checkbox"/> Contingent <input checked="" type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed	Unknown	Unknown
	Date or dates debt was incurred Last 4 digits of account number Specify Code subsection of PRIORITY unsecured claim: 11 U.S.C. § 507(a) (8)	Basis for the claim: Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes		

Debtor **Molecular Templates Opco, Inc.**
NameCase number (if known) **25-10740**

2.3	Priority creditor's name and mailing address Williamson County Tax Collector 904 S. Main St. Georgetown, TX 78626	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input checked="" type="checkbox"/> Contingent <input checked="" type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed	Unknown	Unknown
Date or dates debt was incurred _____		Basis for the claim: _____		
Last 4 digits of account number _____		Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes		
Specify Code subsection of PRIORITY unsecured claim: 11 U.S.C. § 507(a) (8)				

Part 2: List All Creditors with NONPRIORITY Unsecured Claims

3. List in alphabetical order all of the creditors with nonpriority unsecured claims. If the debtor has more than 6 creditors with nonpriority unsecured claims, fill out and attach the Additional Page of Part 2.

			Amount of claim
3.1	Nonpriority creditor's name and mailing address Ace Pipettes, LLC 14230 Prospect Point Drive Cypress, TX 77429 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$1,562.05
3.2	Nonpriority creditor's name and mailing address Acro Biosystems 1 Innovation Way Newark, DE 19711 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$1,217.81
3.3	Nonpriority creditor's name and mailing address Agilent 5301 Stevens Creek Blvd. Santa Clara, CA 95051 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$1,647.50
3.4	Nonpriority creditor's name and mailing address Airgas USA LLC PO Box 734671 Dallas, TX 75373-4671 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$288.40
3.5	Nonpriority creditor's name and mailing address Alliance Advisors, LLC 200 Broadacres Drive Suite 3 Bloomfield, NJ 07003 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Services Performed</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$35,805.00

Debtor **Molecular Templates Opco, Inc.**
NameCase number (if known) **25-10740**

3.6	Nonpriority creditor's name and mailing address Alloy Therapeutics Inc 44 Hartwell Ave Suite 2 Lexington, MA 02421 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$42,601.75
3.7	Nonpriority creditor's name and mailing address AT&T Services, Inc. PO Box 5014 Carol Stream, IL 60197 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$397.09
3.8	Nonpriority creditor's name and mailing address Austin Idealease, LLC 5010 Burleson Rd. Austin, TX 78744 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$1,451.68
3.9	Nonpriority creditor's name and mailing address Austin Welder & Generator Service, Inc. 2004 Howard Lane Austin, TX 78728 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$464.39
3.10	Nonpriority creditor's name and mailing address Baylor Research Institute 3434 Live Oak Dallas, TX 75204 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$2,500.00
3.11	Nonpriority creditor's name and mailing address BD Biosciences 21588 Network Place Chicago, IL 60673 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$5,490.72
3.12	Nonpriority creditor's name and mailing address Bio-Rad Laboratories PO Box 849740 Los Angeles, CA 90084 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$424.39

Debtor **Molecular Templates Opco, Inc.**
NameCase number (if known) **25-10740**

3.13	Nonpriority creditor's name and mailing address BioAgilytix Labs 1320 Soldiers Field Road Brighton, MA 02135 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$43,641.01
3.14	Nonpriority creditor's name and mailing address BioIVT, LLC P.O. Box 770 Hicksville, NY 11802-0770 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$4,208.47
3.15	Nonpriority creditor's name and mailing address BioLegend PO Box 102100 Pasadena, CA 91189 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$5,448.27
3.16	Nonpriority creditor's name and mailing address BioSpace, Inc. 10506 Justin Dr. Urbandale, IA 50322 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$5,247.37
3.17	Nonpriority creditor's name and mailing address Calhoun, Thomson & Matza, LLP PO Box 736044 Dallas, TX 75373 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Services Performed</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$13,500.00
3.18	Nonpriority creditor's name and mailing address Capralogics, Inc. PO Box 356 Hardwick, MA 01037 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$6,000.00
3.19	Nonpriority creditor's name and mailing address CBRE, Inc. PO Box 848844 Los Angeles, CA 90084 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input checked="" type="checkbox"/> Disputed Basis for the claim: <u>Landlord</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$377,117.78

Debtor **Molecular Templates Opco, Inc.**
NameCase number (if known) **25-10740**

3.20	Nonpriority creditor's name and mailing address Cedars Sinai Medical Center 8700 8700 Beverly Blvd. Los Angeles, CA 90048 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: Check all that apply. <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$263,425.74
3.21	Nonpriority creditor's name and mailing address CellCarta Logistics ULC 101 Isley Ave., Unit 5 Darmouth Nova Scotia, Canada Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: Check all that apply. <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$5,507.78
3.22	Nonpriority creditor's name and mailing address CellCarta NV 78-80 Sint-Bavostraat Wilrijk Antwerp Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: Check all that apply. <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$25,766.45
3.23	Nonpriority creditor's name and mailing address Cenetron 2111 W. Braker Lane,Bldg 5 Suite 300 Austin, TX 78758 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: Check all that apply. <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$114,978.67
3.24	Nonpriority creditor's name and mailing address Charles River Labs GPO Box 27812 New York, NY 10087 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: Check all that apply. <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$94,592.50
3.25	Nonpriority creditor's name and mailing address Cogent Communications Inc 2450 N Street NW Washington, DC 20037 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: Check all that apply. <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$2,760.45
3.26	Nonpriority creditor's name and mailing address Computer Packages Inc. 11 N. Washington Street Suite 300 Rockville, MD 20850 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: Check all that apply. <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$5,383.00

Debtor **Molecular Templates Opco, Inc.**
NameCase number (if known) **25-10740**

3.27	Nonpriority creditor's name and mailing address Computershare Inc. 250 Royall Street Canton, MA 02021 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$13,636.50
3.28	Nonpriority creditor's name and mailing address Concur Technologies, Inc. 62157 Collections Center Drive Chicago, IL 60693 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$1,574.04
3.29	Nonpriority creditor's name and mailing address Controlled Contamination Services, Inc 14800 Landmark Blvd. Suite 155 Dallas, TX 75254 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$690.64
3.30	Nonpriority creditor's name and mailing address Cooley LLP 3 Embarcadero Center, 20th Floor San Francisco, CA 94111 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Services Performed</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$97,685.84
3.31	Nonpriority creditor's name and mailing address Corazon Sanders 1950 Hughes Landing Blvd. Apt. 812 Spring, TX 77380 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$11,250.00
3.32	Nonpriority creditor's name and mailing address CT Corporation 28 Liberty Street, 42nd Floor New York, NY 10005 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$15,917.60
3.33	Nonpriority creditor's name and mailing address CTCA Clinical Research, LLC 2520 Elisha Ave. Zion, IL 60099 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$110,878.31

Debtor	Molecular Templates Opco, Inc. Name	Case number (if known)	25-10740
--------	---	------------------------	-----------------

3.34	Nonpriority creditor's name and mailing address Culligan of Austin 110 W Fremont Street Owatonna, MN 55060 Date(s) debt was incurred __ Last 4 digits of account number __	As of the petition filing date, the claim is: Check all that apply. <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$7,316.40
------	---	---	-------------------

3.35	Nonpriority creditor's name and mailing address Danox Environmental Services, Inc. 102 Mary Alice Park Road Suite 104 Cumming, GA 30040 Date(s) debt was incurred __ Last 4 digits of account number __	As of the petition filing date, the claim is: Check all that apply. <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$1,496.00
------	--	---	-------------------

3.36	Nonpriority creditor's name and mailing address Dartmouth-Hitchcock Clinic One Medical Center Drive Lebanon, NH 03756 Date(s) debt was incurred __ Last 4 digits of account number __	As of the petition filing date, the claim is: Check all that apply. <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$87,904.27
------	--	---	--------------------

3.37	Nonpriority creditor's name and mailing address <div style="background-color: black; width: 100px; height: 40px; margin-bottom: 5px;"></div> Date(s) debt was incurred __ Last 4 digits of account number __	As of the petition filing date, the claim is: Check all that apply. <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$13,749.99
------	---	---	--------------------

3.38	Nonpriority creditor's name and mailing address Dell Marketing LP PO Box 676021 Dallas, TX 75267 Date(s) debt was incurred __ Last 4 digits of account number __	As of the petition filing date, the claim is: Check all that apply. <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$11,601.75
------	---	---	--------------------

3.39	Nonpriority creditor's name and mailing address Donnelley Financial, LLC PO Box 842282 Boston, MA 02284 Date(s) debt was incurred __ Last 4 digits of account number __	As of the petition filing date, the claim is: Check all that apply. <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Services Performed</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$50,520.00
------	--	---	--------------------

3.40	Nonpriority creditor's name and mailing address Donohoe Advisory Associates LLC 9801 Washingtonian Blvd Suite 340 Gaithersburg, MD 20878 Date(s) debt was incurred __ Last 4 digits of account number __	As of the petition filing date, the claim is: Check all that apply. <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$130.00
------	---	---	-----------------

Debtor **Molecular Templates Opco, Inc.**
NameCase number (if known) **25-10740**

3.41	Nonpriority creditor's name and mailing address DS Services of America, Inc. PO Box 660579 Dallas, TX 75266 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$460.72
3.42	Nonpriority creditor's name and mailing address Ecolab Inc. /dba Ecolab Pest Elimination 26252 Network Place Chicago, IL 60673 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$3,645.64
3.43	Nonpriority creditor's name and mailing address Ellab, Inc. 303 E 17th Ave Ste 10 Denver, CO 80203 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$4,821.25
3.44	Nonpriority creditor's name and mailing address EMD Millipore 25760 Network Place Chicago, IL 60673 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$4,399.27
3.45	Nonpriority creditor's name and mailing address Equisolve, Inc. 3500 SW Corporate Parkway Suite 206 Palm City, FL 34990 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$2,129.86
3.46	Nonpriority creditor's name and mailing address Equity Plan Solutions 1495 Virginia Ave Redwood City, CA 94061 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$12,500.00
3.47	Nonpriority creditor's name and mailing address eResearch Technology 225 West Station Square Dr Pittsburgh, PA 15219 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$35,430.57

Debtor **Molecular Templates Opco, Inc.**Case number (if known) **25-10740**

Name

3.48	Nonpriority creditor's name and mailing address Ernst & Young U.S. LLP 200 Plaza Drive Ste 2222 Secaucus, NJ 07094 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: Check all that apply. <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Services Performed</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$156,750.00
3.49	Nonpriority creditor's name and mailing address Evoqua Water Technologies LLC 28563 Network Place Chicago, IL 60673 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: Check all that apply. <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$6,078.56
3.50	Nonpriority creditor's name and mailing address Fairjourney Biologics SA Rua do Campo Alegre. n823 Porto Portugal Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: Check all that apply. <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$285,505.87
3.51	Nonpriority creditor's name and mailing address FedEx PO Box 660481 Dallas, TX 75266 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: Check all that apply. <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$15.07
3.52	Nonpriority creditor's name and mailing address Gabriela Gruia Consulting, LLC 350 Albany St. Apt 2D New York, NY 10280 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: Check all that apply. <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Services Performed</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$10,999.98
3.53	Nonpriority creditor's name and mailing address GenScript USA Inc. 860 Centennial Ave. Piscataway, NJ 08854 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: Check all that apply. <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$2,651.50
3.54	Nonpriority creditor's name and mailing address GenServe, LLC 100 Newtown Road Plainview, NY 11803 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: Check all that apply. <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$464.39

Debtor	Molecular Templates Opco, Inc. <small>Name</small>	Case number (if known)	25-10740
--------	--	------------------------	-----------------

3.55	Nonpriority creditor's name and mailing address Gibson, Dunn & Crutcher LLP 333 South Grand Avenue Los Angeles, CA 90071 Date(s) debt was incurred __ Last 4 digits of account number __	As of the petition filing date, the claim is: Check all that apply. <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Services Performed</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$9,974.90
3.56	Nonpriority creditor's name and mailing address Grande Communication Networks LLC PO Box 679367 Dallas, TX 75267 Date(s) debt was incurred __ Last 4 digits of account number __	As of the petition filing date, the claim is: Check all that apply. <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$2,120.00
3.57	Nonpriority creditor's name and mailing address <div style="background-color: black; width: 100px; height: 30px; margin-bottom: 5px;"></div> Date(s) debt was incurred __ Last 4 digits of account number __	As of the petition filing date, the claim is: Check all that apply. <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$20,749.98
3.58	Nonpriority creditor's name and mailing address Horizon Oncology Research, LLC 1345 Unity Place Suite 365 Lafayette, IN 47905 Date(s) debt was incurred __ Last 4 digits of account number __	As of the petition filing date, the claim is: Check all that apply. <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$110.00
3.59	Nonpriority creditor's name and mailing address Ideagen Gael LTD. Mere Way Ruddington Nottinghamshire Scotland Date(s) debt was incurred __ Last 4 digits of account number __	As of the petition filing date, the claim is: Check all that apply. <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$36,250.82
3.60	Nonpriority creditor's name and mailing address Integral Molecular, Inc. 25 N. 38th St. Suite 800 Philadelphia, PA 19104 Date(s) debt was incurred __ Last 4 digits of account number __	As of the petition filing date, the claim is: Check all that apply. <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$3,500.00
3.61	Nonpriority creditor's name and mailing address Joe W. Fly Co. Inc. PO Box 678106 Dallas, TX 75267 Date(s) debt was incurred __ Last 4 digits of account number __	As of the petition filing date, the claim is: Check all that apply. <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$1,413.65

Debtor **Molecular Templates Opco, Inc.**
NameCase number (if known) **25-10740**

3.62 Nonpriority creditor's name and mailing address



Date(s) debt was incurred __

Last 4 digits of account number __

As of the petition filing date, the claim is: *Check all that apply.***\$12,499.98**

- ☐ Contingent
☐ Unliquidated
☐ Disputed

Basis for the claim: Trade debtIs the claim subject to offset? ☒ No ☐ Yes

3.63 Nonpriority creditor's name and mailing address

Life Technologies Corporation
Thermo Fisher Scientific
32822 Collections Center Drive
Chicago, IL 60693

Date(s) debt was incurred __

Last 4 digits of account number __

As of the petition filing date, the claim is: *Check all that apply.***\$2,801.49**

- ☐ Contingent
☐ Unliquidated
☐ Disputed

Basis for the claim: Trade debtIs the claim subject to offset? ☒ No ☐ Yes

3.64 Nonpriority creditor's name and mailing address

LifeSci Advisors
250 W 55th Street
Suite 16B
New York, NY 10019

Date(s) debt was incurred __

Last 4 digits of account number __

As of the petition filing date, the claim is: *Check all that apply.***\$27,501.82**

- ☐ Contingent
☐ Unliquidated
☐ Disputed

Basis for the claim: Services PerformedIs the claim subject to offset? ☒ No ☐ Yes

3.65 Nonpriority creditor's name and mailing address

Linde Gas & Equipment Inc
2301 SE Creekview Drive
Ankeny, IA 50021

Date(s) debt was incurred __

Last 4 digits of account number __

As of the petition filing date, the claim is: *Check all that apply.***\$7,051.29**

- ☐ Contingent
☐ Unliquidated
☐ Disputed

Basis for the claim: Trade debtIs the claim subject to offset? ☒ No ☐ Yes

3.66 Nonpriority creditor's name and mailing address

Marken LLP
145-43 226th St
Springfield Gardens, NY 11413

Date(s) debt was incurred __

Last 4 digits of account number __

As of the petition filing date, the claim is: *Check all that apply.***\$4,635.00**

- ☐ Contingent
☐ Unliquidated
☐ Disputed

Basis for the claim: Trade debtIs the claim subject to offset? ☒ No ☐ Yes

3.67 Nonpriority creditor's name and mailing address

Mary Crowley Medical Research Center
7777 Forest Lane Building C
Suite 707
Dallas, TX 75230

Date(s) debt was incurred __

Last 4 digits of account number __

As of the petition filing date, the claim is: *Check all that apply.***\$76,378.76**

- ☐ Contingent
☐ Unliquidated
☐ Disputed

Basis for the claim: Trade debtIs the claim subject to offset? ☒ No ☐ Yes

3.68 Nonpriority creditor's name and mailing address

Matheson Tri-Gas, Inc.
PO Box 123028
Dallas, TX 75312

Date(s) debt was incurred __

Last 4 digits of account number __

As of the petition filing date, the claim is: *Check all that apply.***\$5,051.33**

- ☐ Contingent
☐ Unliquidated
☐ Disputed

Basis for the claim: Trade debtIs the claim subject to offset? ☒ No ☐ Yes

Debtor **Molecular Templates Opco, Inc.**
NameCase number (if known) **25-10740**

3.69	Nonpriority creditor's name and mailing address Mathys & Squire The Shard32 London Bridge Street London United Kingdom Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Services Performed</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$213,985.76
3.70	Nonpriority creditor's name and mailing address MBL International Corp. 15A Constitution Way Woburn, MA 01801 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$2,850.00
3.71	Nonpriority creditor's name and mailing address Meso Scale Discovery PO Box 75112 Baltimore, MD 21275 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$18,898.31
3.72	Nonpriority creditor's name and mailing address Micro Precision Calibration, Inc. 22835 Industrial Place Grass Valley, CA 95949 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$187.27
3.73	Nonpriority creditor's name and mailing address Nasdaq Corporate Solutions, LLC 151 W 42nd Street New York New York, NY 10036 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$19,018.85
3.74	Nonpriority creditor's name and mailing address Navex Global Inc P.O. Box 60941 Charlotte, NC 28260 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$2,220.44
3.75	Nonpriority creditor's name and mailing address Navigator Business Solutions Inc 180 S. 100 W., Unit 279 Pleasant Grove, UT 84062 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$5,183.01

Debtor **Molecular Templates Opco, Inc.**Case number (if known) **25-10740**

Name

3.76	Nonpriority creditor's name and mailing address Northwest Cancer Centers, PC 1001 Calumet Ave. Dyer, IN 46311 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$134,584.63
3.77	Nonpriority creditor's name and mailing address Northwestern University 633 Clark Street Evanston, IL 60208 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$33,446.67
3.78	Nonpriority creditor's name and mailing address Novotech (Australia) Pty Ltd PO Box 20109 Sydney New South Wales, Australia Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$10,999.36
3.79	Nonpriority creditor's name and mailing address NW Austin Office Partners LLC 2765 Sand Hill Rd, Ste 200 Ste 200 Menlo Park, CA 94025 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Landlord</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$8,478.57
3.80	Nonpriority creditor's name and mailing address NW Austin Office Partners MEARF HoldCo 2765 Sand Hill Road Suite 200 Menlo Park, CA 94025 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Landlord</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$13,170.77
3.81	Nonpriority creditor's name and mailing address NYU School of Medicine One Park Avenue, 5th Floor (5-818) New York, NY 10016 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Landlord</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$241,129.80
3.82	Nonpriority creditor's name and mailing address Pall Life Sciences PO Box 419501 Boston, MA 02241 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$450.55

Debtor **Molecular Templates Opco, Inc.**
NameCase number (if known) **25-10740**

3.83	Nonpriority creditor's name and mailing address Peggy S Edge, CPA, LLC PO Box 204151 Austin, TX 78720 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Services Performed</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$8,500.00
3.84	Nonpriority creditor's name and mailing address Prisma Health-Upstate 900 W. Faris Rd., CTC 3rd Floor Greenville, SC 29605 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$12,288.00
3.85	Nonpriority creditor's name and mailing address ProPharma Group Holdings, LLC 1129 Twentieth St, NW Washington, DC 20036 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$137.50
3.86	Nonpriority creditor's name and mailing address Prudential Overall Supply 1661 Alton Parkway Irvine, CA 92606 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$21,092.33
3.87	Nonpriority creditor's name and mailing address PSI CRO AG Baarerstrasse 113a Switzerland Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$12,533.17
3.88	Nonpriority creditor's name and mailing address Q Squared Solutions Biosciences LLC PO Box 603210 Charlotte, NC 28260 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$75,723.33
3.89	Nonpriority creditor's name and mailing address R&D Systems 614 McKinley Place NE Minneapolis, MN 55413 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$12,815.00

Debtor **Molecular Templates Opco, Inc.**
NameCase number (if known) **25-10740**

3.90	Nonpriority creditor's name and mailing address Resilient Intelligent Networks PO Box 1285 Argyle, TX 76226 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$5,076.82
3.91	Nonpriority creditor's name and mailing address RingCentral, Inc. PO Box 734232 Dallas, TX 75373 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$30,436.96
3.92	Nonpriority creditor's name and mailing address Robinhood Markets, Inc. Say Technologies 85 Willow Road Menlo Park, CA 94025 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$3,543.98
3.93	Nonpriority creditor's name and mailing address Sanford Research 2301 2301 E. 60th Street Sioux Falls, SD 57104 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$62,418.06
3.94	Nonpriority creditor's name and mailing address Sanguine Biosciences, Inc. 5000 Van Nuys Blvd Suite 205 Sherman Oaks, CA 91423 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$6,650.08
3.95	Nonpriority creditor's name and mailing address Sarah Cannon Research Institute, LLC 1100 Dr. Martin L. King Blvd. Suite 800 Nashville, TN 37201 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$49,338.95
3.96	Nonpriority creditor's name and mailing address SHI International Corp PO Box 952121 Dallas, TX 75395 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$2,000.00

Debtor **Molecular Templates Opco, Inc.**
NameCase number (if known) **25-10740**

3.97	Nonpriority creditor's name and mailing address Sigma-Aldrich, Inc. PO Box 535182 Atlanta, GA 30353 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$1,745.66
3.98	Nonpriority creditor's name and mailing address Smartsheet Inc. Smartsheet Inc. Dept 3421 Dallas, TX 75312 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$15,990.00
3.99	Nonpriority creditor's name and mailing address Syneos Health Clinical, Inc. Syneos Clin 1030 Sync Street Morrisville, NC 27560 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$14,576.53
3.100	Nonpriority creditor's name and mailing address The Brandt Companies, LLC PO Box 227351 Dallas, TX 75222 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$1,147.45
3.101	Nonpriority creditor's name and mailing address Thermo Electron N.A. PO Box 742775 Atlanta, GA 30374 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$3,861.94
3.102	Nonpriority creditor's name and mailing address Thomas Scientific, LLC 1654 High Hill Rd., PO Box 99 Swedesboro, NJ 08085 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$55,246.33
3.103	Nonpriority creditor's name and mailing address Three Way Logistics PO Box 1806 Fremont, CA 94538 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$15,210.00

Debtor	Molecular Templates Opco, Inc. Name	Case number (if known)	25-10740
--------	---	------------------------	-----------------

3.104	Nonpriority creditor's name and mailing address Tigermed-BDM, Inc. 100 Franklin Square Dr Suite 305 Somerset, NJ 08873 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$192,353.55
-------	---	--	---------------------

3.105	Nonpriority creditor's name and mailing address Toppan Merrill LLC 1501 Energy Park Drive Saint Paul, MN 55108 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$17,738.24
-------	---	--	--------------------

3.106	Nonpriority creditor's name and mailing address Transperfect Holdings, LLC 1250 Broadway, 7th Floor New York, NY 10001 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$1,270.40
-------	---	--	-------------------

3.107	Nonpriority creditor's name and mailing address U.S. Bank National Association as assignee for Toshiba Finance PO Box 790448 Saint Louis, MO 63179 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$24,861.37
-------	---	--	--------------------

3.108	Nonpriority creditor's name and mailing address University of Miami 1120 NW 14th Street, Room# 874 Miami, FL 33136 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$84,539.51
-------	---	--	--------------------

3.109	Nonpriority creditor's name and mailing address University of Southern California 1441 Eastlake Ave Los Angeles, CA 90033 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$6,713.14
-------	--	--	-------------------

3.110	Nonpriority creditor's name and mailing address Veeva Systems Inc 4280 Hacienda Dr. Pleasanton, CA 94588 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trade debt</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$8,447.00
-------	---	--	-------------------

Debtor **Molecular Templates Opco, Inc.**
NameCase number (if known) **25-10740**

3.111	Nonpriority creditor's name and mailing address Veolia WTS Analytical Instruments, Inc. 6060 Spine Road Boulder, CO 80301 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: Trade debt Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$1,740.93
3.112	Nonpriority creditor's name and mailing address WCG Clinical, Inc. dba WCG IRB, LLC 212 Carnegie Center Suite 301 Princeton, NJ 08540 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: Trade debt Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$334.00
3.113	Nonpriority creditor's name and mailing address Weaver and Tidwell, LLP 2821 2821 West 7th St Suite 700 Fort Worth, TX 76107 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: Services Performed Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$43,312.50
3.114	Nonpriority creditor's name and mailing address Weill Medical College of Cornell Univ. 1300 York Ave New York, NY 10065 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: Trade debt Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$26,232.50
3.115	Nonpriority creditor's name and mailing address XenTech SAS 4, rue Pierre Fontaine Evry France Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: Trade debt Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$16,647.92

Part 3: List Others to Be Notified About Unsecured Claims

4. List in alphabetical order any others who must be notified for claims listed in Parts 1 and 2. Examples of entities that may be listed are collection agencies, assignees of claims listed above, and attorneys for unsecured creditors.

If no others need to be notified for the debts listed in Parts 1 and 2, do not fill out or submit this page. If additional pages are needed, copy the next page.

Name and mailing address

On which line in Part 1 or Part 2 is the
related creditor (if any) listed?Last 4 digits of
account number, if
any**Part 4: Total Amounts of the Priority and Nonpriority Unsecured Claims**

5. Add the amounts of priority and nonpriority unsecured claims.

5a. Total claims from Part 1

5b. Total claims from Part 2

5c. Total of Parts 1 and 2
Lines 5a + 5b = 5c.

Total of claim amounts

5a. \$ **0.00**5b. + \$ **3,760,798.45**5c. \$ **3,760,798.45**

Fill in this information to identify the case:Debtor name **Molecular Templates Opco, Inc.**United States Bankruptcy Court for the: **DISTRICT OF DELAWARE**Case number (if known) **25-10740**☐ Check if this is an amended filing**Official Form 206G****Schedule G: Executory Contracts and Unexpired Leases****12/15****Be as complete and accurate as possible. If more space is needed, copy and attach the additional page, number the entries consecutively.****1. Does the debtor have any executory contracts or unexpired leases?**☐ No. Check this box and file this form with the debtor's other schedules. There is nothing else to report on this form.☒ Yes. Fill in all of the information below even if the contacts of leases are listed on *Schedule A/B: Assets - Real and Personal**Property*

(Official Form 206A/B).

2. List all contracts and unexpired leases**State the name and mailing address for all other parties with whom the debtor has an executory contract or unexpired lease**2.1. State what the contract or lease is for and the nature of the debtor's interest **Engagement agreement dated February 20, 2025**

State the term remaining

List the contract number of any government contract _____

**Morris, Nichols, Arsht & Tunnell LLP
1201 N Market St
#1600
Wilmington, DE 19801**2.2. State what the contract or lease is for and the nature of the debtor's interest **180 Varick St, Suite 806, New York, NY Subtenant Lease**

State the term remaining

List the contract number of any government contract _____

**New York University
550 First Avenue
New York, NY 10016**2.3. State what the contract or lease is for and the nature of the debtor's interest **Engagement agreement dated October 22, 2024**

State the term remaining

List the contract number of any government contract _____

**Rock Creek Advisors, LLC
1738 Belmar Blvd
Belmar, NJ 07719**2.4. State what the contract or lease is for and the nature of the debtor's interest **8900 Amberglen Blvd, Austin, TX Subtenant Lease**

State the term remaining

List the contract number of any government contract _____

**State Farm Mutual Automobile Ins Co
One State Farm Plaza
C-4
Bloomington, IL 61704**

Debtor 1 **Molecular Templates Opco, Inc.**

First Name

Middle Name

Last Name

Case number (if known) **25-10740****Additional Page if You Have More Contracts or Leases****2. List all contracts and unexpired leases**

State the name and mailing address for all other parties with whom the debtor has an executory contract or unexpired lease

2.5. State what the contract or lease is for and the nature of the debtor's interest **Toshiba
e-STUDIO7516ACT**

State the term remaining

List the contract number of any government contract

**Toshiba Business Solutions
Commercentre Dr
Lake Forest, CA 92630**

2.6. State what the contract or lease is for and the nature of the debtor's interest **180 Varick St, Suite
806, New York, NY
Sub-sub tenant Lease
(Tracer DX)**

State the term remaining **192**

List the contract number of any government contract

**TracerDX
180 Varick Street
6th Floor
New York, NY 10014**

Fill in this information to identify the case:Debtor name **Molecular Templates Opco, Inc.**United States Bankruptcy Court for the: **DISTRICT OF DELAWARE**Case number (if known) **25-10740**☐ Check if this is an amended filing**Official Form 206H****Schedule H: Your Codebtors****12/15**

Be as complete and accurate as possible. If more space is needed, copy the Additional Page, numbering the entries consecutively. Attach the Additional Page to this page.

1. Do you have any codebtors?

- ☒ No. Check this box and submit this form to the court with the debtor's other schedules. Nothing else needs to be reported on this form.
- ☐ Yes

2. In Column 1, list as codebtors all of the people or entities who are also liable for any debts listed by the debtor in the schedules of creditors, Schedules D-G. Include all guarantors and co-obligors. In Column 2, identify the creditor to whom the debt is owed and each schedule on which the creditor is listed. If the codebtor is liable on a debt to more than one creditor, list each creditor separately in Column 2.

*Column 1: Codebtor**Column 2: Creditor*

	Name	Mailing Address	Name	Check all schedules that apply:
2.1		Street City State Zip Code		<input type="checkbox"/> D <input type="checkbox"/> E/F <input type="checkbox"/> G
2.2		Street City State Zip Code		<input type="checkbox"/> D <input type="checkbox"/> E/F <input type="checkbox"/> G
2.3		Street City State Zip Code		<input type="checkbox"/> D <input type="checkbox"/> E/F <input type="checkbox"/> G
2.4		Street City State Zip Code		<input type="checkbox"/> D <input type="checkbox"/> E/F <input type="checkbox"/> G

Fill in this information to identify the case and this filing:

Debtor Name Molecular Templates Opco, Inc.

United States Bankruptcy Court for the: _____ District of DELAWARE
(State)

Case number (If known): 25-10740

Official Form 202**Declaration Under Penalty of Perjury for Non-Individual Debtors**

12/15

An individual who is authorized to act on behalf of a non-individual debtor, such as a corporation or partnership, must sign and submit this form for the schedules of assets and liabilities, any other document that requires a declaration that is not included in the document, and any amendments of those documents. This form must state the individual's position or relationship to the debtor, the identity of the document, and the date. Bankruptcy Rules 1008 and 9011.

WARNING -- Bankruptcy fraud is a serious crime. Making a false statement, concealing property, or obtaining money or property by fraud in connection with a bankruptcy case can result in fines up to \$500,000 or imprisonment for up to 20 years, or both. 18 U.S.C. §§ 152, 1341, 1519, and 3571.

Declaration and signature

I am the president, another officer, or an authorized agent of the corporation; a member or an authorized agent of the partnership; or another individual serving as a representative of the debtor in this case.

I have examined the information in the documents checked below and I have a reasonable belief that the information is true and correct:

- ☒ *Schedule A/B: Assets—Real and Personal Property* (Official Form 206A/B)
- ☒ *Schedule D: Creditors Who Have Claims Secured by Property* (Official Form 206D)
- ☒ *Schedule E/F: Creditors Who Have Unsecured Claims* (Official Form 206E/F)
- ☒ *Schedule G: Executory Contracts and Unexpired Leases* (Official Form 206G)
- ☒ *Schedule H: Codebtors* (Official Form 206H)
- ☒ *Summary of Assets and Liabilities for Non-Individuals* (Official Form 206Sum)
- ☐ Amended Schedule _____
- ☒ *Chapter 11 or Chapter 9 Cases: List of Creditors Who Have the 20 Largest Unsecured Claims and Are Not Insiders* (Official Form 204)
- ☐ Other document that requires a declaration _____

I declare under penalty of perjury that the foregoing is true and correct.

Executed on 5/23/2025
MM / DD / YYYY

X /s/ Craig Jalbert
Signature of individual signing on behalf of debtor

Craig Jalbert
Printed name

Chief Executive Officer
Position or relationship to debtor